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SUMMARY 
The cellular prion protein (PrPC) is an extracellular and glycosylphosphatidyl-inositol (GPI)-
linked protein, that is enriched in detergent-resistant membranes (lipid rafts), and 
ubiquitously expressed and highly abundant in the nervous system. It is highly conserved 
among species, with a long, unstructured and flexible tail (FT, residues 23-128), and a 
globular domain (GD, residues 129-231). 
Transmissible spongiform encephalopathies (TSE) are neurodegenerative diseases 
characterized by spongiform changes, neuronal death, astrocytosis, and accumulation of the 
pathological protein PrPSc – an abnormally folded, insoluble and partially protease-resistant 
isoform of the endogenous protein PrPC. 
Whereas it is well established that PrPC is required for PrPSc-mediated toxicity in prion 
infections, suggesting a crucial interaction between PrPSc and PrPC, the mechanisms by which 
aggregated prions are lethal to neurons remain a mystery. Only recently, Mallucci and 
coworkers showed that accumulation of PrPSc causes chronic endoplasmic reticulum (ER) 
stress, in particular persistent translational repression of global protein synthesis by 
phosphorylation of eIF2α, associated with synaptic failure and neuronal loss in prion-infected 
mice. Furthermore, our group uncovered a critical role for the FT of PrPC as the effector 
domain of PrPC-mediated neuronal death. Ligands targeting the α1 and α3 helices of the PrPC 
GD induced rapid neurotoxicity in cerebellar organotypic cultured slices (COCS). However, 
toxicity was prevented when a mutated version of PrPC, harboring deletions within the FT, 
was expressed in COCS, suggesting that the FT has neurotoxic properties and is required to 
transmit the toxic signals originating from the GD. The FT domain contains several different 
motifs and it has been reported to interact with a broad range of proteins, endowing a 
number of potential, yet poorly understood, attributes to the FT, ranging from neurotrophic 
to neurotoxic properties. Clearly, a unifying view of the true function of FT is yet to be 
determined.  
The work presented in this thesis focuses on characterizing the properties of the FT of PrPC in 
vivo, in order to contribute to the understanding of the role of this domain.   
In light of the aforementioned data describing the FT-mediated neurotoxicity, a mouse line 
expressing a membrane-anchored version of the FT of PrPC (FTgpi) was generated and we 
found this protein to be a potent neurotoxin. Mice expressing FTgpi develope severe ataxia 
and die within a few weeks. On histological examination, these mice experienced massive 
loss of cerebellar granule neurons (CGNs) and widespread astrocytosis. The unstructured 
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nature of the protein led us to speculate that FTgpi may trigger ER stress. Indeed, mouse 
cerebelli exhibited a comprehensive ER stress response with significantly increased levels of 
several stress-response markers (spliced XPB1, BiP, CHOP and HSP40). Moreover, we 
demonstrated that FTgpi interacts with BiP, a key chaperone responsible in protein folding 
within the ER. This binding could sequester the availability of BiP to other essential proteins, 
altering the physiological homeostasis of the ER.  
The requirement of an intact FT for the toxicity of anti-GD antibodies, and the similarities 
between the signaling pathways evoked by prions and FTgpi, suggests that the FT may be the 
effector of neurotoxicity in most prion-related conditions. In addition, FTgpi mice may 
represent a safer model, versus working directly with infectious prions, for further 
investigations into the mechanisms of toxicity underlying human prion diseases. 
 
Shadoo (Sho) is a GPI-anchored protein encoded by the Sprn gene. It exhibits homology and 
domain organization similar to the FT of PrPC and is highly conserved among species. A recent 
publication claims that Sho has similar neurotrophic properties to the FT of PrPC, suggesting a 
possible overlapping function.    
Prnpo/o mice develop a chronic demyelinating polyneuropathy (CDP) in the peripheral nerve, 
but not in the central nervous system (CNS), suggesting that the presence of an alternative, 
substitute, protein may prevent the neuropathological phenotype in the CNS but not in 
peripheral nerves, possibly due to its lack of expression. Sho is expressed specifically in the 
CNS, whereas expression in the peripheral nerves is not documented. 
I wished to test the hypothesis that Sho is functionally homologous to the neuroprotective 
function of the FT of PrPC in the CNS, thereby rescuing the phenotype induced by the lack of 
PrP. Mice overexpressing transgenic Sho (by ~2.5 fold) driven by Prnp promoter (Sprn mice), 
which allows Sho expression in peripheral nerves, were kindly provided by Dr. David 
Westaway (University of Alberta, Centre for Research in Neurodegenerative Diseases). I 
crossed Sprn with Prnpo/o mice in order to obtain a mouse line over-expressing Sho under the 
Prnp promoter on a Prnpo/o background. 
Histological examinations and behavioral experiments demonstrated that CPD still presented 
in the periphery of the Sprn/Prnp0/0 mice, indicating that Sho does not influence the 
development of polyneuropathy in peripheral nerve and, therefore, is not the substitute 
protein for PrPC in the CNS. Although the identity of the substitute protein remains unknown, 
this work provides further understanding to the role and function of Sho. 
  ZUSAMMENFASSUNG  
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ZUSSAMENFASSUNG 
Das zelluläre Prion Protein (PrPC) ist ein ubiquitär exprimiertes Protein, das insbesondere im 
Nervensystem nachweisbar ist. Das extrazelluläre PrPC ist durch einen glycosylphosphatidyl-
inositol (GPI) Anker in Detergenzien-resistenten Membranen (DRM) eingebunden und liegt 
dort angereichert vor. Die Aminosäuresequenz des humanen PrPC ist evolutionär hoch 
konserviert und in zwei Proteindomänen unterteilt: einen langestreckten und 
unstrukturierten flexiblen Part (flexible tail, FT, Aminosäuren 23 - 128) und eine C-terminalen 
globuläre Domäne (globular domain, GD; Aminosäuren 129 - 231). Die Akkumulation von 
pathologischem PrPSc, einer missgefalteten, unlöslichen und partiell protease-resistenten 
Isoform des endogenen Proteins PrPC, begleitet von spongiformen Veränderungen, 
neuronalem Zelltod und Astrozytose kennzeichnet die Transmissible Spongiforme 
Enzephalopathien (TSE) als Untergruppe der Enzephalopathien.  
 
Studien haben gezeigt, dass PrPC für die PrPSc assoziierte Toxizität notwendig ist, was auf eine  
Interaktion zwischen PrPC und PrPSc schließen lässt. Allerdingssind die Mechanismen durch 
die Prionen zum Absterben von Nervenzellen führen noch weitestgehend ungeklärt. Erst vor 
kurzem konnte die Arbeitsgruppe um Mallucci et al zeigen, dass die Akkumulation von PrPSc 
zu chronischem Stress im endoplasmatischen Retikulum (ER) und durch die Phosphorylierung 
von eif2α zur Repression der globalen Proteinsynthese in Prionen-infizierten Mäusen führt,   
einhergehend mit Fehlfunktion der Synapsen und neuronalem Zellverlust. Zudem entdeckte 
unsere Forschungsgruppe eine entscheidende Rolle des PrPC FT als Effektor von PrPC 
vermitteltem Zelltod. Die Bindung von Liganden an die α1 und α3 Helix der GD des PrPC führt 
zu rapider Neurotoxizität in zerebellären organotypischen kultivierten Schnitten (COCS). 
Durch Expression einer mutierten PrPC Version mit Deletionen im FT  konnte die Toxizität im 
COCS-Modell unterbunden werden. Dies weist darauf hin, dass der FT neurotoxische 
Eigenschaften besitzt und notwendig ist, um die Signale von der PrPC GD zu vermitteln. Die FT 
Domäne enthält verschiedene Motive, die Studien zufolge mit zahlreichen Proteinen 
interagieren können, was eine Vielzahl an potenziellen neurotrophen bzw. neurotoxischen 
Protein-Protein-Interaktionen ermöglicht Die reguläre Funktion der FT Domäne von PrPC und 
ihr genauer Beitrag zur Pathogenese bleibt bisher ungeklärt.  
Gegenstand dieser Dissertation ist die funktionelle Charakterisierung des FT von PrPC in vivo, 
um seine Bedeutung bei der PrPC vermittelten Toxizität zu verstehen.  
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Zur Beantwortung dieser Frage habe ich eine transgene Mauslinie mit einer in der Membran 
verankerten Version des FT (FTgpi) generiert. Die FTgpi exprimierenden Mäuse, entwickeln 
eine schwere Ataxie und sterben innerhalb von Wochen. Histologische Untersuchungen des 
Gehirns zeigten einen massiven Verlust von zerebellären Körnerzellen und eine 
weitverbreitete Astrozytose. Aufgrund der intrinsisch unstrukturierten Natur des transgenen 
Proteins vermuteten wir hinter der Neurotoxizität die Aktivierung der zellulären Stressanwort 
auf ungefaltete Proteine. Tatsächlich waren einige ERStress Marker in den Kleinhirnen 
betroffener Mäuse signifikant erhöht (spiced XPB1, BIP, CHOP, und HSP40). 
Ich konnte zudem nachweisen, dass FTgpi mit BiP, einem für die Proteinfaltung im ER 
entscheidenden Chaperon, interagiert. Diese Bindung könnte die Verfügbarkeit von BiP für 
andere Proteine reduzieren und so die physiologische Homöostase im ER beeinflussen. 
Die Notwendigkeit eines intakten FT für die Toxizität von Anti-PrP-Antikörpern und die 
Ähnlichkeit der durch Prionen und FTgpi-vermittelten Neurotoxizität lassen vermuten, dass 
der FT  eine bedeutende Rolle bei der Vermittlung von Toxizität in denmeisten PrP-abhängien 
Erkrankungen einnimmt. Die beschriebenen FTgpi Mäuse stellen zudem im Gegensatz zu 
Prionen-infizierten Modellen aus biosicherheitstechnischen Überlegungen ein deutlich 
sichereres Modell zum Studium der pathophysiologischen Mechanismen dar. 
 
 
Shadoo (Sho) ist ein GPI-verankertes Protein, das durch das Sprn Gen kodiert wird. Es hat eine 
Homologie und ähnliche Organisation von Domänen wie der FT von PrPC und ist ebenfalls 
evolutionär hoch konserviert.  Eine kürzlich veröffentliche Studie konnte zeigen, dass Sho 
ähnlich neurotrophe Eigenschaften wie die FT Domäne von PrPC besitzt. Dies deutet auf sich 
überlappende Eigenschaften der Proteine hin. 
Prnpo/o Mäuse entwickeln eine chronische demyeliniserende Polyneuropathie (CDP) des 
peripheren Nervensystems (PNS), nicht aber des zentralen Nervensystems (ZNS). Dies deutet 
auf einen alternativen Substituten für PrPC hin, der den neuropathologischen Phänotyp im 
ZNS, nicht aber im PNS verhindern kann. Sho wird  spezifisch im ZNS exprimiert,  während 
Expression im peripheren Nervensystem nicht dokumentiert ist. 
Ich wollte die Hypothese prüfen, ob Sho im ZNS als funktionelles Homolog der 
neuroprotektiven Funktion von FT PrPC wirkt und damit den Verlust der Funktion von PrPC 
kompensieren kann. 
Transgene Mäuse, die Sho unter dem Prnp Promoter (Sprn Mäuse) überexprimieren (ca 
2.5fach) erlauben die Expression auch im peripheren Nerven und wurden freundlicherweise 
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von Dr. David Westaway (University of Alberta) zur Verfügung gestellt. Ich kreuzte die Sprn-
Mäuse mit Prnpo/o Mäusen, um eine Sho überexprimierende Mauslinie auf einem Prnpo/o 
Background zu erhalten. Histologische Untersuchungen und Verhaltensexperimente haben 
gezeigt, dass die CDP nach wie vor vorhanden ist und Sho keinen Einfluss auf die Entwicklung 
der Polyneuropathie der peripheren Nerven hat. Sho stellt somit keinen funktionellen Ersatz 
für PrPC im ZNS dar. Obwohl die Identität des funktionellen Substituts für PrPC unbekannt 
bleibt, erbrachte diese Versuchsreihe wichtige Einblicke in die Funktion von Sho. 
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ABBREVIATIONS 
AA  amino acid  
AKT  protein kinase B 
Bcl-2   B-cell lymphoma 2 
BSE  bovine spongiform encephalopathy  
CC1   positively charged cluster 1 of PrPC (residues 23-27) 
CC2   positively charged cluster 2 of PrPC (residues 94-110) 
CDP   chronic demyelinating polyneuropathy  
CGC  cerebellar granular cell 
COCS   cerebellar organotypic cultured slices 
CJD   Creutzfeldt-Jakob disease  
fCJD  familial Creutzfeldt-Jakob disease  
sCJD   sporadic Creutzfeldt-Jakob disease  
vCJD   variant Creutzfeldt-Jakob disease  
CNS   central nervous system  
CWD   chronic wasting disease  
DAPI   4,6-diamidino-2-phenylindole 
DNA   deoxyribonucleic acid 
DPL   doppel protein 
DRG   dorsal root ganglia 
ELISA   enzyme-linked immunoassay  
ER   endoplasmic reticulum 
ERK   extracellular-signal-regulated kinase  
FFI   familial fatal insomnia  
FT   N-proximal flexible tail of PrPC (residues 23-124) 
FTgpi                   truncated version of PrPC (PrPΔ141-225) 
GD   globular domain of PrPC (residues 124-230) 
GFAP   glial acidic fibrillary protein  
GPI   glycosylphosphatidyl-inositol  
GSS   Gerstmann-Sträussler-Scheinker disease  
HC   hydrophobic core of PrPC (residues 112-133) 
H&E   hematoxylin and eosin  
HRP   horseradish peroxidase  
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kD   kilo Dalton  
NMR   nuclear magnetic resonance 
OR   octapeptide repeats of PrPC (residues 50-90) 
ORF          open reading frame 
PBS   phosphate-buffered saline  
PK   protease K 
PNGase F  peptide-N4-(N-acetyl-beta-glucosaminyl)asparagine amidase 
POMs   set of 19 anti-PrP monoclonal antibodies [1] 
Prnp   murine PrPC gene locus  
Prnd                 murine Doppel gene locus 
PRNP   human PrPC gene  
Prnpo/o   Prnp knock-out mouse 
PrPC  cellular prion protein 
PrPSc          scrapie-associated prion protein 
PrP∆32-134 truncated version of PrPC (lacking residues 32-134) 
PrP∆94-134  truncated version of PrPC (lacking residues 94-134) 
ROS   radical oxygen species 
rt   room temperature  
SD  standard deviation  
SDS-PAGE  sodium dodecyl sulfate polyacrylamide gel electrophoresis  
sFT                      truncated version of PrPC (lacking residues 141-254) 
sFTΔHC                  truncated version of PrPC (lacking residues 112-254) 
Sho  shadoo protein 
SP   signal peptide 
Sprn  murine Shadoo gene locus 
Sprn-/-  Sprn knock-out mouse 
TUNEL   terminal deoxynucleotidyl transferase dUTP nick end labeling 
T1/2        half-life 
UPR   unfolded protein response 
wt   wild-type mouse 
∆PrP        mutants of PrPC carrying various deletions in the HC domain (e.g.  PrPΔ32-121, 
PrPΔ32-134) [2] 
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CHAPTER 1 
INTRODUCTION 
TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHIES  
Transmissible spongiform encephalopathies (TSEs) are inevitably fatal neurodegenerative 
conditions that affect both humans and animals. Human TSEs include Creutzfeldt-Jakob 
disease (CJD), kuru, fatal familial insomnia (FFI), and Gerstmann-Sträussler-Scheinker 
syndrome (GSS); in animals, they include scrapie in sheep, bovine spongiform 
encephalopathy (BSE) in cattle, and chronic wasting disease (CWD) in cervids [3].  
Stanley B. Prusiner defined as ‘prion’ (generally indicated as PrPSc) the agent causing these 
disorders, thus TSEs are also termed prion diseases [4,5]. Prions stem from the anagram of 
“proteinaceous infectious particles”, and consist solely of proteins which are capable of 
replicating and transmitting infections without the need for informational nucleic acids. The 
latter sets prions apart from conventional infection agents such as viruses and bacteria. 
Griffith was the first to suggest that the infectious agent is merely a protein and it is devoid of 
nucleic acids, but it was only accepted after the systematic work conducted by Prusiner [5,6]. 
In support of this conjecture, experimental evidence that prions are resistant to different 
enzymatic, chemical and physical procedures employed to destroy nucleic acids, but are 
sensitive to treatments that denature proteins, had accumulated [5-8]. Follow up 
experiments aiming at identifying the protein responsible for TSEs, pinpointed PRNP as the 
endogenous gene coding for a 37 kDa protein, designated as PrPC [4,9,10]. At this point, an 
audacious hypothesis was proposed: prions consist of misfolded infectious proteins which 
propagate, and act as a template for the conversion of the endogenous cellular form of the 
protein, PrPc, into misfolded prions, PrPSc [11,12]. 
Although many similarities to other neurodegenerative protein misfolding diseases such as 
Alzheimer’s, Huntington’s and Parkinson’s disease have been described [13,14] prion diseases 
are unique in that they are transmissible. However, this concept is evolving and prion-like 
transmissibility has lately been characterized for other amyloidosis diseases as well [15-17]. 
For instance, only recently it has been shown that the intracerebral and intraperitoneal 
inoculation of β-amyloid–containing brain extracts can induce cerebral β-amyloidosis and 
associated pathologies in susceptible hosts [17], suggesting that, like prion disease, cerebral 
β-amyloidosis can be seeded in the brain by homologous protein aggregates delivered into 
the peritoneal cavity [17]. However, unlike mice infected with prions, those inoculated with 
amyloid-beta (Aβ) do not die. Hence, the transmission of Aβ and PrP differs conspicuously in 
CHAPTER 1 TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHIES 
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the neurological effects they induce in their hosts, the difference being no less than a matter 
of life and death [18].   
 
PRION DISEASES IN ANIMALS 
Animal TSEs include, among others, scrapie in sheep and goat, BSE in cattle, transmissible 
mink encephalopathy (TME), and CWD in deer and elk [19]. Scrapie was recognized as early 
as 1738, characterized by the affected animals scraping their fleeces, stumbling and 
behavioral changes [19]. Although the origin of scrapie remains completely obscure, the 
pathology and transmissibility of this disease are today clearly understood. CWD has been 
known of since the late 1960s and was first reported as fatal wasting disease in captive mule 
deer in Colorado [20]. To date, 10% of the wild deer population in Colorado and Wyoming is 
thought to be affected [21]. As for scrapie, the origin of CWD remains elusive. CWD is 
believed to be transmitted among cervids with high efficiency, but transmission to other 
species has not been demonstrated [22]. 
BSE was first reported in the United Kingdom in 1985; the pathologic changes in the brain 
tissue of the animals were similar to those described for TSEs. The emergence of BSE was 
possibly caused by transmission of sheep scrapie to cattle through infected feed prepared 
from rendered carcasses [23,24]. This new form of TSE, commonly referred to as ‘mad-cow 
disease’, rapidly developed into a major global epidemic that peaked in the first half of the 
1990s. Since then, the incidence of BSE has decreased in all affected Western European 
countries due to regulations that prevent feeding ruminant meat and bone meal to 
ruminants, and stringent prion testing of slaughtered cattle. Although incidence is declining, 
cases have been documented in the US as well as in countries previously believed to be BSE-
free. Additionally, scrapie outbreaks are constantly documented in Europe. The fact that, 
most likely, millions of people (primarily in the United Kingdom) have been in contact with 
BSE-contaminated meat, prion diseases still present a major challenge, and vigilance needs to 
be maintained to prevent future outbreaks [25]. 
 
PRION DISEASES IN HUMANS 
Humans TSEs include Creutzfeldt-Jakob disease (CJD), kuru, fatal familial insomnia (FFI), and 
Gerstmann-Sträussler-Scheinker syndrome (GSS). Human prion diseases are classified as 
inherited, infectious or sporadic disorders, according to clinical signs, genetic and 
neuropathological findings [19]. Frequently, rapid cognitive decline and progressive 
dementia, myoclonus, cerebellar impairment and ataxia characterize prion diseases. Once 
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clinical symptoms appear, death follows very rapidly [19]. Prion diseases are influenced by an 
amino acid polymorphism resulting in a methione > valine substitution at PrP codon 129 [26], 
caused by the single nucleotide polymorphism (SNP) ATG-to-GTG. Individuals who carry this 
specific SNP have been found to be predisposed to contracting CJD.   
CJD has a very low incidence (~ 1 person in one million per year) and it was initially described 
as a sporadic disease (sCJD) [3]. The cause of sCJD is not fully understood – somatic mutations 
in the PRNP gene have been suggested to underlie this disease; alternatively, some 
individuals may possess a genetic background with a propensity, albeit very low, for PrPC to 
self-assemble into aggregates of PrPSc leading to spontaneous manifestation of this disease 
[25].   
Acquired conditions may occur after exposure to infectious material, as seen in variant CJD 
(vCJD), kuru, and iatrogenic CJD [19]. When BSE arose, scientists had proposed that BSE could 
have been transmitted to humans as a new variant form of vCJD. A dramatic increase of 
human TSEs, epidemiological, biochemical and neuropathological evidence, although indirect, 
have suggested that this was the case [3,27-29]. The incidence of vCJD appears to be 
decreasing, but a ≥30-year incubation period for BSE/vCJD is not implausible [3], and another 
rise in the incidence of vCJD has been proposed [30]. Until the middle of the 20th century, 
Kuru was the primary cause of death in Papua New Guinea [31]. Kuru is caused by the 
ingestion of tissues of the central nervous system (CNS) during ritualistic anthropophagy by 
New Guinea tribes. The incidence has steadily fallen following the cessation of cannibalism in 
Papua New Guinea [30]. Iatrogenicity refers to the accidental transmission of a disease, in 
this case CJD, during the course of medical procedures [19,32,33]. Neurosurgical equipment 
in particular is a prime example of the route for transmission [34], underscoring the 
importance of sensitive diagnostic tools which could be used for screening units prior to 
transfusions or surgical operations.  
Familial TSEs account for 10-20% of all TSE cases in humans and include genetic CJD (gCJD), 
GSS and FFI [19]. Several mutations in the PRNP gene have been identified in families with 
hereditary or genetic gCJD, and inheritance of these mutations is autosomally dominant with 
high penetrance [3]. GSS is another autosomal-dominantly inherited and transmissible TSE, 
caused by mutations in the prion protein open reading frame (ORF) [3,35,36]. GSS typically 
presents with progressive cerebellar ataxia or spastic parapesis and cognitive decline and was 
first reported in an Austrian family in 1928, and again in 1936 when another member of the 
same family was affected [37]. Fatal familial insomnia (FFI) was initially described in 1986 in 
an Italian family that was affected by insomnia and dysautonomia [38]. FFI was classified as a 
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TSE once transmission to mice had been demonstrated [39]. FFI predominantly affects the 
thalamus region of the brain, and clinical signs typically include deregulation of the sleep-
wake cycle and attention deficit [40].   
Interestingly, all inherited TSEs appear early in life, possibly due to the presence of abnormal 
PrP throughout development and postnatal life. In contrast, sporadic prion diseases may 
occur because of a stochastic event. 
 
PRION CONVERSION REACTION 
The prevailing hypothesis on the nature of the infectious prion is the ‘protein-only’ 
hypothesis. This proposes that the agent causing the infectious disease consists essentially of 
the abnormally folded PrPSc [41].  
Prion diseases are associated with abundant accumulation of PrPSc in the CNS. PrPSc and PrPC 
were found to share a similar amino acid structure, and no known covalent modifications 
have been found to differentiate the two proteins [42]. However, the resolution of the 3-
dimensional (3D) structure of mouse, hamster and human PrPC by nuclear magnetic 
resonance (NMR) [43-45] has provided some evidence for a possible conversion mechanism. 
It has therefore been proposed that PrPSc is a posttranslational derivative of PrPC, having 
acquired a different 3D conformational structure, and that pathologic PrPSc operates as a 
seed promoting further conversion of PrPC [46]. How PrPC is converted to PrPSc remains 
unclear, but two likely conversion processes, the ‘template-directed refolding’ model and the 
‘seeded nucleation’ model [47-49] have been proposed and are depicted in Figure 1.1. 
Indeed, it has been shown that PrPC and PrPSc can be distinguished because of their different 
biochemical profiles: PrPC is rich in α-helices (~ 45%) and has relatively few β-sheets; PrPC is 
soluble, and sensitive to proteinase K (PK) digestion, whereas PrPSc is enriched in β-sheet 
content (~ 45%) and is therefore prone to aggregation; PrPSc is insoluble in detergents, and 
partially resistant to PK [3,50]. 
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Figure 1.1 Proposed models for the conversion of PrPC into PrPSc. (a) The ‘template-directed refolding 
model’ posits an interaction between PrPSc and PrPC. The latter is subsequently induced to transform 
itself into PrPSc. A high energy barrier may prevent spontaneous conversion of PrPC into PrPSc. (b) The 
‘seeded nucleation model’ proposes that PrPC and PrPSc are in a thermodynamic equilibrium, strongly in 
favor of PrPC. Only a highly ordered seed of several monomeric PrPSc molecules can further recruit 
monomeric PrPSc entities and eventually generate larger aggregates with an amyloid structure. Within 
such a crystal-like seed, PrPSc becomes stabilized. Fragmentation of PrPSc aggregates increases the 
number of seeds, which can then recruit further PrPSc and thus replicate the prion agent. Adapted from 
Aguzzi and Polymenidou, 2004 [23]. 
 
A) The ‘template-directed refolding’ presumes that a high activation energy barrier prevents 
spontaneous conversion of PrPC into PrPSc, and that the conformational change is kinetically 
controlled. Exogenous PrPSc exerts a catalytic action and lowers the energy barrier, hence 
promoting the misfolding process. In familial prion diseases, pathogenic mutations may lower 
the energy barrier favoring spontaneous conversion into PrPSc with no necessity of exogenous 
PrPSc.  
B) The ‘seeded nucleation’ model assumes that PrPC and PrPSc are in a thermodynamic 
equilibrium, strongly favoring PrPC in a nondisease state. A highly ordered seed of PrPSc can 
be stabilized on contact with other seeds and, in turn, further recruits additional monomeric 
PrPSc, resulting in amyloid. Subsequent fragmentation of PrPSc aggregates increases the 
number of infectious seeds, which can recruit further PrPSc and thus results in apparent 
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replication of the agent. In this model, the formation of the seed is the rate limiting step. 
Aggregates need to be continuously fragmented, generating an increasing number of seeds 
to result in exponential accumulation of PrPSc [51]. 
In support of the ‘protein-only’ hypothesis, mice devoid of the prion protein PrPC (Prnpo/o 
mice) have been shown to be completely resistant to prion infection [52]. In addition, in 
Prnpo/o mice previously inoculated with prions, the brain tissue does not harbor prion 
infectivity [53]. Reintroduction of Prnp by transgenesis restores susceptibility and prion 
replication in Prnpo/o mice [54-56]. These findings suggest that PrPC acts as an essential 
substrate for the propagation of the infectious agent.  
Currently, it is widely accepted that prions mainly consist of PrPSc. However, it remains to be 
formally proven whether the infectious unit consists exclusively of PrPSc. 
 
PRION DISEASE HALLMARKS AND PATHOGENESIS 
Although the clinical profiles differ among the distinct prion diseases, the histological 
hallmarks of brain damage are similar, and are represented by the presence of PrPSc 
aggregate deposits, synaptic alteration, extensive spongiform degeneration, astrogliosis, and 
neuronal loss [57]. These result in clinical symptoms which include cognitive and motor 
dysfunctions (Figure 1.2) [58]. 
Since neuronal loss and gliosis accompany many other conditions of the CNS, it is the 
spongiform change that is mostly specific to prion diseases [57]. Spongiform changes may be 
mild, moderate or severe and are characterized by diffuse or focally clustered, small, round or 
oval vacuoles in the neuropil of the deep cortical layers, cerebellar cortex or subcortical grey 
matter, which might become confluent [57]. Presence and distribution of spongiform change 
vary greatly between cases and disease subtypes. For instance, some prion diseases have 
equivocal, little, or no spongiform change, such as FFI, which is specifically characterized by 
prominent thalamic atrophy with profound astrogliosis [59]. 
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Figure 1.2. Histopathological hallmarks of prion diseases. From left to right. PrPSc deposits, which are 
detected by anti-PrP antibody, are induced by the abnormal aggregated conformer of PrPC, PrPSc; 
synaptic and dendritic loss (visualized by silver staining), vacuolization and spongiosis (H&E staining), 
astrogliosis and brain inflammation (shown by GFAP staining), neuronal death (TUNEL and caspase-3 
staining). Adapted from Soto and Satani [58]. 
 
Despite decades of intense research in prion diseases, the mechanisms and molecular 
determinants of prion pathogenesis leading to gliosis, spongiosis, and neuronal cell loss are 
not yet fully understood. Prnp0/0 mice do not present with major abnormalities or neuronal 
loss, suggesting that prion diseases are not caused by PrPC loss-of-function [60]. Furthermore, 
Prnp0/0 mouse models do not support prion replication, nor do they show clinical signs of 
cognitive impairment and motor dysfunction after prion inoculation [52], indicating that PrPC 
is necessary for PrPSc replication, which in turn leads to neurodegeneration, and that PrPSc 
might not be directly responsible for prion-dependent neuronal loss. In addition, prion 
infection after grafting PrPC-overexpressing brain tissue onto Prnp0/0 brains resulted in PrPSc 
propagation, with pathological changes restricted to the grafted area [61,62]. Further 
investigations have shown that transgenic mice expressing an anchorless form of PrP were 
still capable of replicating prions, but without signs of pathology, indicating that membrane-
anchoring of PrP is also necessary to induce pathology [63]; and depletion of endogenous 
neuronal PrPc in mice with established neuroinvasive prion infection reversed early 
spongiform change and prevented neuronal loss and progression to clinical disease [64]. 
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These findings indicate that prion propagation and neurotoxicity may be distinct and 
independent events, and that neurotoxicity is somehow transduced through the expression 
of cellular PrPC on target cells [64].  
Charles Weissmann has proposed that toxicity could be mediated by PrP forms other than 
PrPSc, for instance a toxic intermediate generally denoted as PrP* (Weissmann, 1991a), 
offering an explanation for those cases when spongiform pathology is present with few PrPSc 
deposits [19]. In recent years, the concept that oligomeric and even smaller units, rather than 
larger aggregates, might be responsible for neurotoxicity in many neurodegenerative 
disorders that are accompanied by misfolded aggregates has been discussed [65]. Indeed, it 
has been proposed that larger aggregates may actually have a protective function [65]. When 
abnormal and aggregated proteins cannot be refolded or degraded by proteasomal 
degradation and autophagy, cells have an alternative line of defense whereby aggregates are 
sequestered by microtubule-mediated transport and collected at a single cytoplasmic site 
near the centriole. This process generates a large inclusion body called an ‘aggresome’ 
[65,66]. 
In 2012, Moreno et al showed for the first time that accumulation of PrPSc during prion 
infection causes persistent translational repression of global protein synthesis in mice, 
indicating an association between endoplasmic reticulum (ER) stress and neurodegeneration 
[67]. Moreover, ER stress has been detected in patients with Parkinson’s disease [68], 
Alzheimer’s disease [69], and amyotrophic lateral sclerosis (ALS) [70,71]. However, whether 
ER stress is a cause or consequence of neurodegenerative processes in such diseases is 
currently not known.               
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THE CELLULAR PRION PROTEIN 
BIOSYNTHESIS AND EXPRESSION PATTERN OF PRPC 
PrPC is a glycosylphosphatidyl inositol (GPI)-linked glycoprotein enriched in detergent-
resistant membranes (lipid rafts), and synthesized in the rough ER [3]. PrPC comprises 253 
amino acids which undergo post-translational modifications such as removal of the signal 
peptide (1-22aa), addition of two glycosylation chains (highly branched glycosyl groups with 
sialic acid substitutions) at asparagine 181 and 197, formation of a disulfide bridge between 
cysteine 197 and 214, and attachment of a GPI anchor after replacement of a C-terminus 
peptide (Figure 1.3) [72]. 
The cellular prion protein is highly conserved among species. It has been identified in 
mammals, birds [73], amphibians [74], and fish [75], suggesting that PrPC may play an 
important functional role, although Prnpo/o mice have no significant impairments and have a 
normal life span [52].  
PrPC is highly expressed in the central nervous system, predominantly within neurons, 
although it is also expressed by other neural cell lineages including astrocytes and 
oligodendrocytes [76], whereas expression on microglia is minimal [77]. It is also expressed at 
high levels in a broad range of peripheral tissues and cells including heart, skeletal muscle, 
kidney and lymphocytes [78,79]. In addition, ectopic PrPC expression and prion replication 
competence can be induced by inflammatory conditions in organs that physiologically express 
very low amounts PrPC [80].  
 
THE PHYSIOLOGICAL FUNCTION OF PRPC  
Despite many efforts, and advances in the characterization of PrPC, its physiological role is still 
unclear. To date, the study of Prnp0/0 mice has failed to elucidate the molecular function of 
this highly conserved protein. It seems rather unlikely that a highly conserved protein has 
evolved solely to bestow susceptibility to prion diseases upon organisms [19]. Although 
Prnpo/o mice are viable, they show a chronic demyelinating polyneuropathy (CDP) in 
peripheral nerves [81]. Interestingly, CDP develops if PrPC is solely ablated from neurons, but 
it is prevented when PrPC is specifically ablated in Schwann cells [81]. This confers an 
important role for neuronal PrPc in peripheral nerve myelin maintenance [81]. 
Many other functions have been proposed for PrPC, such as modulation of cell signaling, 
maintenance of circadian rhythms and neuronal development [82]; however, their 
significance in these processes has not been confirmed. Furthermore, several dozen proteins 
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have been described to bind neuronal PrPc in various cellular compartments [3,83] although, 
in most cases, there are no known associated biological functions for these interactions. One 
cannot exclude that PrPC exerts diverse roles according to the cellular context, local 
environment and its interaction partners [84]. It has therefore been hypothesized that PrPc 
acts as a scaffold protein and has the ability to drive the assembly of multi-component 
complexes at the cell surface [84].  
 
STRUCTURE OF PRPC 
The structure of mature PrPC is well-conserved comprising a long, unstructured and flexible 
tail (FT, residues 23-128), and a globular domain (GD, residues 129-231) of three α-helices 
and a two-stranded antiparallel β-sheet that flanks the first α-helix (Figure 1.3A) [85,86]. The 
FT contains several different domains: the signal peptide (SP), the small charge cluster one 
domain (CC1), the octarepeat region (OR) and the charge cluster two domain (CC2) (Figure 
1.3A). The hydrophobic core (HC) is a stretch of 20 hydrophobic amino acids that separates 
the FT from the GD (Figure 1.3A) [45]. The HC is highly conserved among species which may 
reflect an important biological function [3]. Accordingly, a number of mice carrying different 
mutations involving the HC (generally defined as ΔPrP mice) have been created in order to 
clarify the role of this region; the loss of HC leads to very severe disorders in newborn mice, 
causing death within 8 days on a Prnp0/0 background [2].      
 
 
 
Figure 1.3. The structure of PrPC and the products of α- and β-cleavage. (A) FT: flexible tail; GD: 
globular domain. PrPC comprises signal peptide (SP; shown in orange), which is cleaved at the level of 
the endoplasmic reticulum, the octarepeat region (OR; shown in green), the charge cluster 1 and 2 
domain (CC1 and CC2; pale blue), the hydrophobic core domain (HC; dark grey), three α-helices (H1, H2, 
H3; yellow) And a glycosylphosphatidyl inositol anchor (GPI; red). The two glycosylation sites are at 
N181 and N197. A disulfide bridge is also present, connecting C179 and C214. (B) Fragments generated 
by α- and β-cleavage.  
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PrPC undergoes proteolytic cleavage that generates an N-terminal fragment (N1) and a C-
fragment (C1) (Figure 1.3B). Evidence suggests that ADAM9/ADAM10 or ADAM17 metallo-
proteases are involved in this proteolytic process [87]. This α-cleavage occurs approximate to 
the 111/112 peptidyl bond; it can be either constitutive or regulated by protein kinase C 
(PKC), and has been hypothesized to be a key regulator of PrP function and/or malfunction 
[88]. Different roles have been attributed to C1, such as the regulation of p53-dependent 
staurosporine-induced caspase-3 activation in cell systems [89]; however its precise role 
remains elusive. A second cleavage site, the β-cleavage site, has been identified immediately 
before the CC2 domain, approximate to the 92/93 peptidyl bond (Figure 1.3B) [90]. Although 
attempts have been made, both in vitro and in vivo, to characterize and describe the 
functions of the products of these cleavages, their physiological roles remain unknown.  
 
PRPC DOUBLE AND SHADOW 
Since it is well conserved amongst different species, PrPC must possess some beneficial 
physiological attribute; however, results from Prnpo/o mice only partially untangled the 
physiological function of PrPC. Another avenue of research into the biology of PrPC has 
recently discovered two paralogs of PrPC, Doppel and Shadoo, the ‘double’ and ‘shadow’ of 
PrPC, respectively [91].  
Doppel is predominantly expressed in the testis and it appears to have a crucial role in the 
proper functioning of the male reproductive system [92]. It is encoded by the Prnd gene in 
mice, which is located 16 kilobase (kb) downstream of the murine Prnp locus [93]. Doppel is 
processed similarly to PrPC: it migrates through the secretory pathway to the plasma 
membrane, where it resides in lipid rafts in testis of wild type (wt) mice [94]. The tertiary 
structure of Doppel is very similar to the GD of PrPC, sharing the same secondary structure 
elements, despite their primary sequence sharing only 25% homology [95]. Interestingly, 
overexpression of Doppel in the CNS of Prnpo/o mice correlates with ataxia and death of 
cerebellar neurons [96], although the mechanistic aspects of this deleterious effect are 
unknown.  
Shadoo (Sho) is a CNS-expressed protein which has many similar properties with PrPC and 
may possess overlapping activity [97]. Shadoo is encoded by the Sprn gene, and seems to be 
widely conserved in nature, from lower organisms (e.g. zebrafish) to rodents and primates 
[98]. In contrast to Doppel, the architecture of Shadoo is similar to that of the PrPC FT, 
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although Shadoo lacks an OR region [91]. As previously mentioned, the HC is the most 
conserved region of PrPC, suggesting functional homology across species [91].         
Over the past 14 years, research efforts have focused on the biology of PrPC and its family 
members in order to clarify their functional roles; as yet, the full picture is yet to be disclosed.  
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AIMS OF THIS THESIS 
Prion diseases affect both humans and many species of animals, and no effective treatment is 
currently available. Although recent publications point to ER stress as a major culprit for 
synaptic impairments and neurodegeneration in prion-infected mice, the exact mechanisms 
and cellular processes by which prions kill neurons are not fully understood. Furthermore, 
our group recently showed that antibodies targeting the α1 and α3 helices of the GD are 
surprisingly neurotoxic, and their toxicity is strictly dependent on an intact FT of PrPC, 
uncovering a pivotal role of the FT domain in PrP-induced toxicity [99].  
In light of this evidence, I wished to investigate: 
 
• the role of FT of PrPC in triggering neuronal death in vivo, by means of a newly 
generated transgenic mouse line expressing a redacted version of the prion protein 
lacking the GD but retaining the GPI anchor signal (PrPΔ141-225 or FTgpi).                            
In particular, I focused on identifying:  
o FT structural determinants involved in toxicity 
o the signaling pathways evoked by FT 
o the temporal occurrence of these pathways 
 
 
 
Prnpo/o mice show CDP in peripheral nerves [81]. Shadoo is a CNS-expressed protein which 
has structural homology with the FT of PrPC, and it has been shown to share some of its FT 
neuroprotective properties [97]. Therefore, I wished to elucidate:  
• the predicted role of Shadoo in reversing the CDP observed in peripheral nerves in 
Prnpo/o mice. Mice overexpressing transgenic Sho ~2.5-fold, driven by the Prnp 
promoter, were kindly provided by Dr. David Westaway (University of Alberta, Centre for 
Research in Neurodegenerative Diseases). These mice were crossed with Prnpo/o mice in 
order to obtain mice over-expressing Sho on a Prnpo/o background. The severity of 
CDP was assessed at different time points by immunohistochemistry, ultrastructure 
analysis and behavioral experiments. 
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CHAPTER 2 
MEMBRANE TETHERING OF THE FLEXIBLE TAIL OF THE PRION 
PROTEIN TRIGGERS UNFOLDED PROTEIN RESPONSE AND 
NEURODEGENERATION  
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INTRODUCTION 
THE CONTROVERSIAL ROLE OF THE FLEXIBLE TAIL (FT) OF PRPC 
PrPC consists of an unstructured, flexible N-terminal tail (FT, residues 23-128) hinged to a 
structured globular domain (GD, residues 129-231) comprising three α-helices (α1, α2 and 
α3) and two-stranded antiparallel β-sheets [45]. Although unstructured, the amino acid 
sequence of the FT identifies a number of recognizable motifs: the signal peptide (SP), the 
small ‘charge cluster 1’ (CC1), a series of octapeptide repeats (OR), the ‘charge cluster 2’ 
(CC2), and the hydrophobic core (HC) – a stretch of 20 hydrophobic amino acids linking the FT 
with the GD (Figure 1.3). CC2 and HC together form the central domain (CD). All these motifs 
have been reported to interact with a broad range of proteins, conferring a number of 
potential, yet poorly understood, attributes to the FT, ranging from neurotrophic to 
neurotoxic properties [100], Clearly, the true function of these domains is still to be 
determined.  
 
A ROLE FOR FT IN NEUROPROTECTION 
Several mouse models carrying deletions in the HC domain (PrPΔ32-121, PrPΔ32-134 and PrPΔ111-134, 
collectively denoted as ‘ΔPrP’), demonstrate the intrinsic neuroprotective role of the PrP HC 
motif [100]. Expression of ΔPrP, or neuronal expression of Doppel, which resembles the GD of 
PrPC but lacks the FT section, cause demyelination in the CNS and peripheral nerves, 
indicating that PrPC, through its HC domain, is required for myelin maintenance [2,81,101]. 
Amino acids 23-90, encompassing the CC1 and OR domains, also showed neuroprotective 
properties – Doppel induced neurodegeneration when ectopically expressed in the CNS [96], 
but this phenotype was completely reversed when the first 133 aa of PrPC were fused to 
Doppel (NH2-PrP(1-133)-Doppel) [102]. Importantly, when either CC1 or OR were removed from 
the chimera protein, Doppel-mediated toxicity could not be inhibited [103]. Moreover, it has 
been shown that the N-terminal fragment of PrP (N1), which contains the CC1, OR and CC2 
domains, also displays in vivo and in vitro neuroprotective functions by modulating the p53 
pathway [104]. 
The entire or partial loss of HC leads to very severe neurological disorders and early postnatal 
death in newborn mice [2,56,105], whereas mice carrying shorter deletions within the FT did 
not display neurological symptoms [2]. Importantly, introduction of one copy of wt PrPC 
abrogated the deleterious effect in ΔPrP mice [56].  
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A ROLE FOR FT IN NEUROTOXICITY 
The mechanism by which ΔPrP mutations leads to neurodegeneration in vivo is not known. 
Recently, in vitro studies showed how ΔPrP mutants induce spontaneous large cationic 
unspecific channel activity in HEK293 cells [106], suggesting that neurotoxicity could be 
elicited by the formation of a pore in the plasma membrane, which would destabilize the 
membrane potential. Deletion of the small CC1 domain from these variants reverses toxicity 
both in vitro [106] and in vivo [107], highlighting the importance of FT domains, in particular 
CC1, in modulating neurotoxicity in these models. Furthermore, mice expressing PrPC devoid 
of CC1 display reduced susceptibility to prion infection and greatly reduced levels of PrPSc 
[108], suggesting that CC1 may not be essential for, but dramatically improves, prion 
propagation.  
Further evidence supporting the pivotal role of the FT domain in PrP-induced toxicity has 
been demonstrated by Sonati et al [99]. Antibodies targeting the α1 and α3 helices of the GD 
are neurotoxic, and we recently found that their toxicity is strictly dependent on an intact FT 
[99]. These phenomena may be explained through an allosteric mechanism of action: 
conformational transitions in the GD may influence the topology of the FT relative to the 
plasma membrane or other cellular constituents, and eventually trigger a cascade of 
untoward events. In support of the idea that FT domains are crucial for PrP-induced toxicity, 
removal of the OR region from the FT, or pretreatment with anti-OR antibodies, abolishes the 
toxicity of anti-GD antibodies, indicating that an intact FT is required to transmit these toxic 
signals [99].  
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OUTLINE OF THIS WORK 
Currently, controversial opinions surround the physiological and pathological role of FT. In 
light of our recent findings [99], I focused on the neurotoxic properties of FT. In order to 
clarify the mechanisms by which FT exerts detrimental actions in vivo, we generated 
transgenic mice expressing the FT fused to a GPI anchor but devoid of the entire GD (PrPΔ141-
225, henceforth termed ‘FTgpi’). FTgpi mice experience progressive, inexorably lethal 
neurodegeneration. In contrast, mice expressing untethered, soluble FT (sFT) do not 
experience any pathology. Immunofluorescence and fluorescence-activated cell sorting 
(FACS) analysis showed that most FTgpi was retained in the ER with only a minor fraction 
reaching the plasma membrane. FTgpi triggered chronic ER stress in vivo at an early time 
point, which in turn induced apoptosis, potentially explaining the neuronal death observed in 
the cerebellum of FTgpi mice, where the protein is mostly expressed. These phenomena are 
strikingly similar to those observed in prion infections [67], suggesting that aberrant 
localization of FT or acquisition of illegitimate FT topologies may underlie the toxicity 
observed in these diseases. Therefore, FTgpi mice may be a useful tool for further 
investigation into the mechanisms of toxicity underlying human prion diseases.  
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RESULTS 
GENERATION OF TRANSGENIC MICE AND ANALYSIS OF PROTEIN EXPRESSION 
To investigate the ability of FT to elicit toxicity in vivo, a redacted version of the prion protein 
lacking the GD but retaining the GPI anchor signal (PrPΔ141-225 or FTgpi; Figure 2.1A) was 
cloned into the ‘half-genomic’ pPrPHG backbone, which contains the Prnp gene devoid of 
intron #2 [54]. The resulting construct was injected into pronuclei of Prnp+/+ mice. Potential 
founders were screened by tail PCR for the presence of the transgene, and six founders were 
identified as carriers. Three transgenic lines (FTgpi155, FTgpi157, and FTgpi177) were 
selected for further analysis on the basis of transgenic protein expression levels in the CNS 
(Figure 2.1B). FTgpi was visualized by western blot as a double band at 15 kDa and 17 kDa, 
potentially suggesting that FTgpi assumes different transmembrane topologies affecting 
cleavage of its signal peptide. The highest FTgpi-expressing founder, FTgpi157, and its 
offspring died before further analysis could be performed. This was the first indirect 
observation suggesting that FTgpi could be toxic.  
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Figure 2.1. Layout of FTgpi protein and founder FTgpi expression level. (A) Scheme of wild-type PrP 
and FTgpi utilized for the generation of the transgenic mouse. SP: signal peptide; OR: octapeptide 
repeats; CC2: charge cluster 2; HC: hydrophobic core; α1 α2 α3: α-helices; GPI: 
glycosylphosphatidylinositol anchor. POM2 binds the degenerate epitope QPHGGG/SW (aa 57-64, 64-
72, 72-80, 80-88) whereas POM11 recognizes the epitope QPHGGSW (aa 64-72, 72-80) of the FT [1]. (B) 
Whole brains of FTgpi, Prnpo/o (here and henceforth used as a negative control) and B6/J-Hsd1 mice 
(BL6, here and henceforth used as positive control) were analyzed by Western blotting using POM11. 
Arrows: FTgpi protein (15 and 17 kDa). The FTgpi157 founder mouse showed the highest expression 
levels of FTgpi. 
 
The two remaining lines (FTgpi155 and FTgpi177) were crossed with Prnpo/o mice to obtain 
offspring on a Prnpo/o background. Transgenic mRNA levels in FTgpi155 brains were ~6-fold 
higher than Prnp mRNA in C57BL/6 mice (BL6; Figure 2.2A), yet FTgpi protein levels were just 
15% (FTgpi155) and 5% (FTgpi177) of total PrPC in BL6 brains (Figure 2.2B), suggesting that 
the FTgpi protein undergoes very rapid degradation. 
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Figure 2.2. mRNA and protein level of FTgpi protein. (A) Transgenic FTgpi and wt PrP transcription 
quantified by Real-Time PCR (RT-PCR). FTgpi mRNA was approximately 6-fold higher than Prnp mRNA. 
(B) Brain homogenates were subjected to PNGase F treatment. FTgpi155 and FTgpi177 mouse lines 
displayed protein levels of ~15% and ~5%, respectively, compared to a calibration curve with serially 
diluted BL6 brain (not shown). Western blots using POM2.  
 
PATHOLOGICAL PHENOTYPES OF MICE EXPRESSING FTGPI  
All FTgpi transgenic lines were maintained in both Prnp+/+ and Prnpo/o genetic backgrounds. 
We used the ZyFISH technique [109] to reliably discriminate between homo- and hemizygous 
transgene carriers. Mice were monitored according to a previously published four-degree 
clinical score [2]. Both the FTgpi155 and the FTgpi177 line developed a phenotypically similar 
form of ataxia. Since each line was derived from an independent pronuclear microinjection 
leading to unique chromosomal integration events, I concluded that the phenotype was 
induced by the expression of the transgene rather than by insertional mutagenesis.  
The first sign of disease (~9 weeks) observed in FTgpi155 Prnp+/+ was shivering, followed by 
mild limping and hind limb weakness. At later stages (~12 weeks), mice tended to fall on both 
sides while walking in the cage (Figure 2.3, left panel). In addition, mice were placed on a 
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metal grid and monitored for 5 min to assess their walking proficiency (cage grid test). At 
later stages of the disease (~14 weeks), these tests always resulted in positive scores, with 
both legs consistently falling through the grid (Figure 2.3, central and right panels). No 
paralysis was observed.  
 
 
 
Figure 2.3. FTgpi mice phenotype. Typical clinical phenotypes at terminal stage. Left panel: FTgpi155+/+ 
mouse showing ataxia symptoms at 14 weeks of age. Central and right panel: representation of a grid 
test. At 14 weeks of age, FTgpi155+/+ legs repeatedly falling through the grid.  
 
The higher-expressing lines, FTgpi155 Prnp+/+ and FTgpi155 Prnpo/o, developed signs of 
disease and died significantly earlier (median ± standard deviation: 109 ± 6.7 and 111 ± 24 
days, respectively, p<0.0001) than the lower expressing lines FTgpi177 Prnp+/+ and FTgpi177 
Prnpo/o (242 ± 127 and 479 ± 178 days, respectively, p<0.0001), indicating that FTgpi toxicity 
was dose-dependent (Figure 2.4). Co-expression of PrPC did not improve the survival of FTgpi 
mice (Figure 2.4). This suggests that the mechanism of toxicity is different from that of the 
deletion mutants, PrPΔ94-134 and PrPΔ32-134 [2,56], which are dose-dependently rescued by co-
expression of PrPC [2]. On the contrary, PrPC seemed to worsen the phenotype in FTgpi177 
mice, as FTgpi177 Prnp+/+ died significantly earlier that FTgpi177 Prnpo/o mice (Figure 2.4, 
orange and green lines). This phenomenon did not occur in FTgpi155 mice, perhaps because 
FTgpi expression was saturating. 
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Figure 2.4. Survival curves of FTgpi mice. 
Absence (x Prnpo/o) or presence (x Prnp+/+) of 
full-length PrP. The number of mice is 
indicated in the legend. Higher expressor 
FTgpi155 Prnp+/+ and FTgpi155 Prnpo/o mice 
died significantly earlier than FTgpi177 
Prnp+/+ (p<0.0001) and FTgpi177 Prnpo/o 
(p<0.0001) mice respectively, suggesting 
that toxicity is dose-dependent. FTgpi177 
Prnp+/+ mice died significantly earlier than 
FTgpi177 Prnpo/o mice (p<0.001), indicating that PrPC may exacerbate the phenotype. Statistics: Log-
Rank (Mantel-Cox) test. 
 
FTGPI INDUCES CEREBELLAR DEGENERATION 
Histological examination of brain sections of clinically affected FTgpi mice revealed 
conspicuous pathological changes in the cerebellum. All FTgpi lines displayed a similar 
phenotype consisting of progressive loss of cerebellar granule neurons (CGNs) in both 
hemispheres (Figure 2.5, arrows), substantial reduction in the width of the granule cell layer, 
widespread atrophy (Figure 2.5, H&E), and intense astrocytosis (Figure 2.5, GFAP).  
 
 
 
Figure 2.5.Brain histology of FTgpi mice. (H&E) H&E staining showing severe atrophy of the cerebellum 
and conspicuous loss of CGNs in FTgpi177 mice compared to controls (left panels; arrows indicate loss 
of CGNs); (right panels) GFAP-stained cerebellum showing widespread astrogliosis in FTgpi177 mice. 
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Interestingly, Purkinje cells were well-preserved. As the “half-genomic” pPrPHG vector is not 
expressed in Purkinje cells [110], this suggests that FTgpi toxicity is cell-autonomous and does 
not propagate to other cell types. No obvious pathology was present in other regions of the 
brain, likely due to the lower expression level of FTgpi (Figure 2.6).  
 
 
Figure 2.6. FTgpi expression level in 
brain and cerebellum. Both FTgpi155 
and FTgpi177lines showed increased 
FTgpi expression in the cerebellum. 
Western blot was probed with POM2 
antibody. 
 
No other organs of the body had detectable levels of FTgpi (Figure 7A) and 
immunohistochenical analyses revealed that all were found to be pathologically unaffected 
by the FTgpi transgene (Figure 7B).  
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Figure 2.7. H&E staining of FTgpi177 organs (A) Western blotting using POM11 show FTgpi expression 
exclusively in the brain. Unspecific bands are present in both FTgpi and BL6 blots. (B) No abnormalities 
were reported in liver, spleen, kidney, heart, stomach, pancreas and intestine.   
 
Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) detects DNA 
fragmentation resulting from apoptosis or other forms of cell death. CGNs of FTgpi177 mice 
already showed nuclear TUNEL signals at 5 weeks of age, which became widespread by 10 
weeks (Figure 2.8A). Strikingly, mice did not show any symptoms at this stage. At 28 weeks, 
the signal was reduced, probably due to the removal of dead neurons by microglia.  
4',6-diamidino-2-phenylindole (DAPI) staining confirmed the progressive loss of CGNs in the 
cerebellum (Figure 2.8A), which was further reflected in progressive decrease of FTgpi 
expression over time (Figure 2.8B). 
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Figure 2.8. Cerebellar 
pathology in FTgpi mice.        
(A) Cerebellar frozen sections 
were stained with DAPI (blue) 
and TUNEL (red) to reveal 
nuclei and fragmented DNA, 
respectively. A gradual loss of 
CGNs is evident in the 
granular layer. Numerous 
TUNEL+ cells were detected at 
10 weeks in FTgpi mice. 
Frozen sections of age-
matched Prnpo/o controls were 
stained at all respective time 
points (shown at 28 weeks) 
and did not reveal any TUNEL+ 
cells. (B) Western blot using 
POM11 showed FTgpi protein 
expression decreasing over 
time in the cerebellum, 
possibly as a consequence of 
the progressively reduced 
number of neurons.  
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At 50 weeks, TUNEL+ cells shifted from the granular layer to the molecular layer and white 
matter (Figure 2.8A), and the TUNEL signal became localized to the cytoplasm of microglia  
(Iba1+ cells) (Figure 2.9A), suggesting neuronophagia by the latter. Accordingly, microglia 
showed a strong cytoplasmic FTgpi signal (Figure 2.9B).  
 
 
 
Figure 2.9.Microglia engulfing dead CGNs. (A) Cerebellar frozen sections were stained with DAPI 
(blue), Iba1 (yellow) and TUNEL (purple) to reveal nuclei, fragmented DNA, and microglia respectively. 
TUNEL signal localized to the cytoplasm of microglia. (B) Cerebellar frozen sections were stained with 
DAPI (blue), Iba1 (red) and POM11 (yellow) to reveal nuclei, microglia, and FTgpi. A strong FTgpi signal 
was detected in the cytoplasm of microglia. 
 
 
FTGPI IS RETAINED IN THE ER 
In order to study the biogenesis of FTgpi, the wild-type PrPC and FTgpi reading frames were 
cloned into the expression plasmid pBMN, which was used to generate retroviral particles 
using the Phoenix Retrovirus Expression System (Orbigen). These particles were employed to 
infect HPL cells, a hippocampal cell line which lacks PrPC expression [111], in order to create 
stably-transfected cell lines expressing either FTgpi or PrPC. FTgpi lacks the two N-
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glycosylation sites that are located in the GD, and was expressed as an unglycosylated 15 kDa 
protein in HPL cells (Figure 2.10). 
 
 
Figure 2.10. FTgpi expression in HPL 
cells. Stably transfected HPL cell lysates 
were subjected to PNGase F treatment 
as indicated and analyzed by Western 
blotting using POM11. FTgpi does not 
have glycosylation sites and appears as 
a single band at 15 kDa. 
 
In order to obtain insight into the mechanism of FTgpi toxicity, I compared the subcellular 
localization of FTgpi and PrP. The surface of live HPL cells stably transfected with either full-
length PrPC or FTgpi was co-stained with the plasmalemmal marker CmDil and POM11, an 
antibody against the FT of PrPC which recognizes both PrPC and FTgpi [1]. As expected, PrPC 
was highly expressed and colocalized with CmDil, whereas no immunofluorescent signal was 
detected for FTgpi (Figure 2.11A), although the total FTgpi expression level was similar to that 
of PrPC (Figure 2.10).  
FACS analysis on live cells confirmed that much less FTgpi was present on the plasma 
membrane than PrPC, as the FTgpi signal (Figure 2.11B, red line) was slightly stronger than the 
background (grey line, HPL-GFP) but much weaker than PrPC (blue line). This suggests that 
FTgpi undergoes abnormal processing, and that its transport to the plasma membrane may 
be impaired.  
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Figure 2.11. Immunofluorescence on stably transfected HPL-PrP and HPL-FTgpi cells. FTgpi does not 
reach the plasma membrane. POM11 stains both PrP and FTgpi. (A) Cells were stained with the surface 
marker CmDil (yellow), fixed, and stained with POM11 followed by Alexa 647 anti-mouse IgG secondary 
antibody (purple), and counter-stained with DAPI (blue) to visualize the nuclei. As expected, PrP showed 
colocalization with the surface marker CmDil (yellow), whereas FTgpi failed to be expressed on the 
plasma membrane. Confocal images were processed with Imaris; Colocalization was calculated using 
the function ImarisColoc. (B) FACS analysis: cells were stained with POM11, followed by Alexa 647 anti-
mouse IgG secondary antibody. Each plot is representative of three biological replicates (left panel; 
HPL-GFP [grey line, background fluorescence], HPL-FTgpi [red line] and HPL-PrP [blue line, positive 
control]). Median fluorescence intensity (MFI) was dramatically lower for HPL-FTgpi compared with 
HPL-PrP (right panel), indicating its scarce expression on the plasma membrane. ****P<0.0001 by 
unpaired two tails t-test. 
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Next, fixed and permeabilized cells were co-stained with calnexin, an ER marker, and POM11. 
Both PrPC and FTgpi were found to colocalize with calnexin, confirming their presence in the 
ER (Figure 2.12).  
 
 
Figure 2.12. Immunofluorescence on stably transfected HPL-PrP and HPL-FTgpi cells. FTgpi localizes 
in the ER lumen. Cells were fixed, permeabilized and stained with calnexin antibody, to label the ER, 
and with POM11, followed by Alexa 555 anti-rabbit (yellow) and Alexa 647 anti-mouse (purple) IgG 
secondary antibodies, respectively. Blue: DAPI nuclear stain. Both PrP and FTgpi showed colocalization 
within the ER. Confocal imagines were processed with Imaris; Colocalization was calculated using the 
function ImarisColoc. 
 
Conversely, PrPC was found to co-localize within the Golgi, as expected, but FTgpi was not 
(Figure 2.13A). In addition, cells were stained solely with POM11 to compare the intracellular 
distribution of PrP versus FTgpi (Figure 2.13B). The vast majority of HPL-PrP showed a 
characteristic Golgi-like staining (Figure 2.13B, white arrows), which was absent within HPL-
FTgpi cells. This suggests that FTgpi was unable to leave the ER.  
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Figure 2.13. Immunofluorescence on stably transfected HPL-PrP and HPL-FTgpi cells. FTgpi does not 
reach the Golgi apparatus. (A) Cells were fixed, permeabilized, and stained with giantin antibody 
labeling the Golgi apparatus (yellow), as well as POM11 (purple), followed by Alexa 647 anti-mouse 
and Alexa 555 anti-rabbit IgG secondary antibodies., Blue: DAPI. PrP partially but specifically 
colocalized with giantin, indicating that most PrP was in the ER. However, only a faint colocalization 
signal was detected in HPL-FTgpi. (B) Cells were fixed and stained with POM11 (purple), followed by 
Alexa 647 anti-mouse IgG secondary antibody, and reacted with DAPI (blue) to stain the nuclei. White 
arrows point at the characteristic Golgi-staining, which is widely present in HPL-PrP cells, whereas HPL-
FTgpi cell do not show such signal. HPL-GFP were transfected with the pBMN empty-vector and used as 
control for unspecific signals. Confocal imagines were processed with Imaris; colocalization was 
calculated using the function ImarisColoc. 
 
Co-staining with LAMP2, a lysosome marker, did not show colocalization with either PrPC or 
FTgpi (Figure 2.14).  
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Figure 2.14. Immunofluorescence on stably transfected HPL-PrP and HPL-FTgpi cells. FTgpi does not 
localize in lysosomes. Cells were fixed and stained with LAMP2 antibody to mark the lysosomes 
(yellow) and POM11 (purple), followed by Alexa 647 anti-mouse and Alexa 555 anti-rabbit IgG 
secondary antibodies, and reacted with DAPI (blue) to stain the nuclei. Neither PrP nor FTgpi showed 
colocalization with LAMP2. Confocal imagines were processed with Imaris; colocalization was 
calculated using the function ImarisColoc. 
 
 
FTGPI IS DEGRADED BY PROTEASOMES 
The expression level of FTgpi protein in mouse brains was only ~15% of that of PrPC in wild-
type mice, despite much higher mRNA levels, suggesting that FTgpi may be actively degraded 
in vivo. Using HPL cells expressing either PrP or FTgpi, we quantified the expression level of 
these proteins by Western blot upon treatment with a battery of compounds that selectively 
inhibited either lysosomes (NH4Cl, Bafilomycin, Leupeptin) or proteasomes (MG132, 
Lactacystin) after 4 and 8 h. PrPC resides physiologically on the plasma membrane, where it is 
endocytosed and recycled to the membrane [112] or alternatively degraded through 
lysosomes [113]. As anticipated, PrPC level increased upon lysosomal inhibition (Figure 
2.15A), for which NH4Cl, which inhibits lysosome acidification, was particularly effective. 
Bafilomycin and Leupeptin, which specifically inhibit the vacuolar-type H+-ATPase and the 
cysteine, serine and threonine peptidases, respectively, also increased PrPC expression levels 
in cells, albeit not as dramatically as NH4Cl.   
In contrast, FTgpi expression was not altered with lysosomal inhibition; however, it was 
significantly increased upon proteasome inhibition (Figure 2.15B). This suggests that FTgpi 
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could be retro-translocated from the ER into the cytosol to be degraded by the proteasome 
machinery. 
 
Figure 2.15. NGPI is degraded through proteasomes. HPL-PrP and HPL-NGPI cells were treated for 4 
and 8 h with either lysosomes inhibitors (NH4Cl, Bafilomycin, Leupeptin) or proteasomes inhibitors 
(MG132, Lactacystin). (A) Lysates of HPL-PrP cells were analyzed by Western blotting using POM11. The 
level of PrP increased significantly upon treatment with lysosomes inhibitors. Graph: quantification of 
the respective Western blots. (B) Lysates of HPL-FTgpi cells were analyzed by Western blotting using 
POM11. The level of FTgpi specifically increased upon treatment with proteasome inhibitors. Each bar 
indicates the mean ±SEM of 4 biological replicates. **P<0.01 and *P<0.05 by two-way ANOVA with 
Bonferroni multiple comparisons post-test (each bar is compared to the Untreated).  
 
Some of these drugs may have pleiotropic effects. For instance, proteasome inhibitors (e.g. 
MG132) could induce transcriptional up-regulation of the cytomegalovirus promoter, which 
in turn could substantially enhance synthesis of ectopic proteins [114]. We therefore 
investigated the mechanism of FTgpi clearance using an alternative method in order to 
confirm the data. We used pulse-chase experiments in combination with Bafilomycin and 
MG132. We transiently transfected HPL cells with either FTgpi or PrPC, then I metabolically 
labeled the cells with [35S]methionine/cysteine for 1 h and either harvested directly or chased 
for different intervals of time in 35S-free culture medium before lysis. FTgpi and PrP were 
immunopurified with POM2, and analyzed by SDS-PAGE. As anticipated, PrPC turnover was 
significantly reduced upon lysosomal inhibition and its half-life (T1/2) could not be measured, 
whereas a T1/2 of approximately 4 h was obtained with proteasome inhibition, which was 
comparable to unhibited cells (Figure 2.16A). In contrast, FTgpi degradation was drastically 
impaired upon proteasome inhibition, yet it was unaffected by lysosomal inhibition (T1/2 ~ 2.2 
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h) compared to the untreated condition (T1/2 ~ 2.6 h) (Figure 2.16B). This confirmed that cells 
degrade FTgpi through the proteasome machinery. 
 
 
 
Figure 2.16. FTgpi is degraded through proteasomes. HPL cells were transiently transfected with PrP 
or FTgpi, and metabolically labeled with [35S]Met/Cys for 20 min at 37 °C. Then, cells were either lysed 
after the pulse or incubated in culture medium without 35S at 37 °C for 1, 2, 4, 6, and 8 h, respectively, in 
presence of either DMSO (untreated), Bafilomycin (a lysosomes inhibitor) or MG132 (a proteasomes 
inhibitor). Proteins were immunoprecipitated with POM2 and subjected to SDS-PAGE and 
autoradiography. (A) Left panel: PrP turnover was impaired upon treatment with Bafilomycin but not 
MG132. Right panel: evaluation of autoradiograms: the amounts of protein are expressed as 
percentage of total protein rescued directly after the labeling period and plotted as a function of the 
chase time points. (B) Left panel: FTgpi turnover was impaired upon treatment with MG132 but not 
Bafilomycin. The data points were fitted to an exponential curve using nonlinear regression analysis. 
 
 
FTGPI INDUCES CHRONIC ER STRESS IN VITRO 
Our observations on the cellular turnover of FTgpi, together with the fact that FTgpi contains 
an exposed core of 20 hydrophobic amino acids that is likely to be targeted by the ER quality 
control system, raised the possibility that FTgpi may elicit ER stress and the unfolded protein 
response (UPR). The UPR is mediated by three families of signal transducers: Activating 
Transcription Factor 6 (ATF6), Protein kinase-like Endoplasmic Reticulum Kinase (PERK) and 
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Serine/threonine-protein-kinase/endoribonuclease (IRE1), which sense the conditions of 
protein folding in the ER lumen and relay the information to the cell through many different 
mechanisms, including regulated proteolysis (ATF6), translational control (PERK) and 
nonconventional mRNA splicing (IRE1) [115].  
I used stably transfected HPL cells to measure ER stress markers by immunoblot. HPL-FTgpi 
cells exhibited significantly increased phosphorylation levels of both PERK (Figure 17A) and 
eIF2α (Figure 17B) when compared with HPL-GFP. Hence, FTgpi robustly activates the PERK 
pathway. Moreover, C/EBP-homologous protein (CHOP) expression was also found to be 
slightly increased (Figure 17C), and its mRNA was significantly augmented (Figure 17D). 
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Figure 2.17. FTgpi induces ER stress in vitro. Cell lysates were analyzed by Western blot. Numbers 
denote independent experiments. p-PERK (A) and p-eIF2α (B) were significantly higher in HPL-FTgpi 
than in HPL-GFP cells. p-PERK blot: non-consecutive lanes of the same blot. p-PERK/PERK and                  
p-eIF2α/eIF2α ratios were calculated after values were normalized with actin. (C) CHOP was also found 
to be increased in HPL-FTgpi cells. (D) CHOP mRNA was quantified by RT-PCR. Thapsigargin (Tg)-treated 
cells were used as positive control. CHOP was significantly upregulated in HPL cells expressing FTgpi. (A-
B-C) Each bar indicates the average ± SEM of 3 or 6 biological replicates. ** P<0.01 and *P<0.05 by 
unpaired two-tails t-test (each bar is compared to HPL-GFP). (D) Each sample is representative of 4 
biological replicates. Error bars indicate averages ± SEM. **P<0.01 by one-way ANOVA with Bonferroni 
multiple comparisons post-test (each sample is compared to HPL-GFP).  
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Similar results were obtained when HPL-FTgpi were compared to HPL-PrP cells (Figure 2.18). 
 
 
 
Figure 2.18. FTgpi, but not PrP, triggers ER stress in HPL cells. Cell lysates were analyzed by Western 
blot using the indicated antibodies. Numbers: biological replicates. (A) p-PERK and p-eIF2α were 
significantly increased in HPL-FTgpi cells. Values were normalized with actin. Each bar indicates the 
mean ±SEM of 3 biological replicates. *P<0.05 by unpaired two-tails t-test (each bar is compared to 
HPL-PrP).  
 
Next, I investigated the status of the IRE1 pathway by examining specifically the spliced 
version of XBP1. Thapsigargin (Tg)-treated cells were used as positive controls, as Tg robustly 
induces ER stress. Surprisingly, the level of spliced XBP1 in HPL-FTgpi cells was not altered 
compared to HPL-PrP (Figure 2.19). Secondly, I assessed the mRNA expression level of the 
most common markers of ER stress, whose expression is increased by the activation of ATF6 
(GRP78, HERP1, EDEM1, ERP72, HSP40) [116,117]. Only HERP1 was found to be slightly 
upregulated (Figure 2.19). Together these data suggest that IRE1and ATF6 may not be key 
players in the process leading to toxicity in vitro.  
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Figure 2.19. Transcriptional analysis of additional ER stress markers. Tg: Thapsigargin. Cells were 
treated with 0.5 µM Tg for 3 h at 37°C in order to induce ER stress as positive controls for our primers. 
mRNA levels were quantified by RT-PCR. Major players involved in the IRE1 and ATF6 pathways, such as 
spliced XBP1 and BIP respectively, were unaltered in vitro. Black triangles: non-treated cells; white 
triangles: Tg-treated cells. *P<0.05 by one-way ANOVA with Bonferroni multiple comparisons post-test. 
 
FTGPI INDUCES CHRONIC ER STRESS IN VIVO 
In order to verify the involvement of ER stress in vivo, I performed the same analysis using 
mRNA derived from cerebellum of asymptomatic FTgpi155 Prnpo/o mice. mRNA levels of 
spliced XBP1, BIP, CHOP, and HSP40 were all significantly upregulated compared to age-
matched Prnpo/o control mice (Figure 2.20A), indicating that FTgpi causes a comprehensive ER 
stress response in vivo, where IRE1, PERK and ATF6 seem to be all involved. Importantly, ER 
stress was detected in FTgpi mice at a stage where no cerebellar degeneration was yet to be 
observed, suggesting that ER stress is an upstream event that may lead to the subsequent 
neurodegenerative process.  
Increased phosphorylation levels of PERK were also observed in cerebellar homogenates of 
FTgpi mice (Figure 2.20B), supporting the evidence of ongoing ER stress in vivo. 
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Figure 2.19. Figure 2.20. FTgpi induces ER stress in vivo (A) mRNA was extracted from cerebellum of 
FTgpi155 and Prnpo/o mice. mRNA levels of ER stress markers were quantified by RT-PCR. XBP1, BIP and 
CHOP were found to be significantly upregulated. *P<0.05 and **P<0.01 by unpaired two-tails t-test. 
(B) Cerebellum homogenates of FTgpi177 and Prnpo/o mice were analyzed by Western blot. p-PERK was 
increased in cerebellum of FTgpi177 mice. The blot was first probed with a p-PERK antibody, stripped 
for 20 min, and then re-probed with PERK antibody. Each bar indicates the mean ±SEM of 3 biological 
replicates. *** P<0.001 by unpaired two-tails t-test (each bar is compared to BL6). 
 
FTGPI BINDS ‘BINDING IMMUNOGLOBULIN PROTEIN’ (BIP) IN VIVO 
BIP binds to IRE1, PERK and ATF6 in unstressed cells and dissociates from these UPR sensors 
during acute ER stress. In ER stress conditions, a chronic presence of unfolded proteins would 
saturate the free pool of chaperones, titrating BIP away from IRE1, hence activating the UPR 
signaling [118,119]. Further, it has been shown that misfolded proteins in the ER that do not 
interact with BIP failed to induce the UPR [119]. I examined whether FTgpi interacts with BIP 
by immunoprecipitation experiments. I pulled down FTgpi on brain homogenates of FTgpi155 
mice using POM2. I found that POM2 specifically co-precipitated BIP in samples where FTgpi 
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was expressed, whereas no band was detected in Prnpo/o control mice (Figure 2.21). I 
concluded that FTgpi binds BIP in vivo.  
 
 
 
Figure 2.21. FTgpi binds BIP in vivo. Brain homogenates of FTgpi155 and Prnpo/o mice were incubated 
overnight with POM2 to precipitate FTgpi. Precipitates were analyzed by Western blot. Left panel: total 
extract. Right panel: immunoprecipitates, showing that BIP specifically co-precipitated with FTgpi, as no 
signal was detected in Prnpo/o mice.      
 
THE HC DOMAIN IS REQUIRED FOR FTGPI CYTOTOXICITY  
Our previous investigations indicated that FTgpi elicits ER stress by triggering the UPR, 
primarily through the activation of PERK in vitro. I then sought to define the domains of FTgpi 
required for activating this pathway. I employed the Flp-In™ 293 T-Rex cell line (Invitrogen) to 
generate stably transfected cell lines ensuring a homogenous expression of our proteins of 
interest. The following constructs were cloned into the pcDNA5/FRT vector: PrP, FTgpi, an 
anchorless version of FTgpi (sFT or PrPΔ141-254), and an anchorless version of FTgpi devoid of 
the HC domain (sFTΔHC or PrPΔ112-254). Cells transfected with the empty vector were defined as 
HEK-pcDNA5. Upon co-transfection with our vectors and pOG44, which encodes the Flp 
recombinase, hygromycin-resistant clones were pooled together. HEK-PrP expressed sizeable 
levels of PrPC protein, whereas all other mutants failed to express high levels (Figure 2.22A). 
All mutants with low protein expression also displayed low mRNA level (Figure 2.22B), 
suggesting that negative selection occurred against those mutants, possibly because of their 
toxicity.  
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Figure 2.22. Poor expression level of FTgpi, sFT and sFTΔHC in stably transfected Flp-In™ 293 T-Rex 
cells. Flp-In™ 293 T-Rex cells were stably transfected by using pcDNA5/FRT vector containing the coding 
sequence for PrP, FTgpi, sFT or sFTΔHC, and the respective cell lines were generated. (A) Cell lysates were 
analyzed by Western blot using POM2. HEK-PrP cells show a strong signal, whereas the other lines 
failed in expressing comparable levels of protein. Overexposure of the blot allowed the detection of 
FTgpi, sFT and sFTΔHC. (B) mRNA level was quantified by RT-PCR. mRNA of HEK-PrP was set as 100%. 
 
Notably, despite the low expression levels, HEK-FTgpi induced higher phosphorylation of 
eIF2α than HEK-pcDNA5 (Figure 2.23). HEK-PrP also displayed increased phosphorylation of 
eIF2α (Figure 2.23), albeit to a lesser degree than HEK-FTgpi, which was expected considering 
the exceptionally high expression of the protein. Interestingly, HEK-sFT cells showed a 
comparable level of p-eIF2α as seen with HEK-FTgpi (Figure 2.23), suggesting that anchoring 
to the membrane may not be crucial to trigger ER stress. Conversely, HEK-sFTΔHC cells do not 
show increased phosphorylation of eIF2α, indicating that deletion of the HC suffices to 
alleviate FTgpi-induced ER stress.  
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Figure 2.23. FTgpi induces phosphorylation of eIF2α in HEK cells. Cell lysates were analyzed by 
Western blot using eIF2α and p-eIF2α antibodies. p-eIF2α/p-eIF2α ratio was calculated after values 
were normalized to actin. Each bar indicates the mean ±SEM of 3 biological replicates. *P<0.05 by 
unpaired two-tails t-test (each bar is compared to HEK-pcDNA5).  
 
FTGPI INFLUENCES PROTEIN KINASE B (AKT) PHOSPHORYLATION LEVEL   
The AKT cascade is a critical pathway regulating cell survival, and its deactivation deprives 
cells of signals allowing them to withstand apoptotic stimuli [120]. Sustained phosphorylation 
of eIF2α inactivates AKT by moderating its phosphorylation state [121]. I found decreased 
phosphorylation of AKT in HEK-PrP, HEK-FTgpi, and HEK-sFT cells (Figure 2.24A). As for eIF2α, 
deletion of the HC abrogates the effect on AKT (Figure 2.24A). A similar signal was also 
detected in HPL cells (Figure 2.24B).  
Hence, chronic deactivation of AKT may be involved in the loss of CGNs observed in vivo.  
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Figure 2.24. FTgpi reduces AKT phosphorylation in vitro. Cell lysates were analyzed by Western blot 
using AKT and p-AKT antibodies. p-AKT/AKT ratio was calculated after values were normalized to actin. 
(A) HEK cells (B) HPL cells. Numbers: biological replicates. p-AKT was significantly decreased in both 
HEK- and HPL-FTgpi cells. Each bar indicates the mean ±SEM of 3 biological replicates. *** P<0.001 by 
unpaired two-tails t-test (each bar is compared to (A) HPL-pcDNA5 or (B) HPL-PrP). 
 
Therefore, I tested the level of phosphorylated AKT in vivo. Unlike in vitro, I found increased 
levels of phosphorylated AKT in cerebellar homogenates of FTgpi177 mice (Figure 2.25), 
suggesting that differences could be present between the in vitro and in vivo models. The 
discrepancy has been discussed in the Discussion session.  
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Figure 2.25. FTgpi increases AKT phosphorylation in vivo. Cerebellum homogenates of FTgpi177 and 
Prnpo/o mice were analyzed by Western blot. p-AKT was increased in cerebellum of FTgpi177 mice. Blot 
was first decorated with p-AKT antibody, stripped for 20 min, and stained with AKT. 
 
FTGPI DECREASES ERK1/2 PHOSPHORYLATION IN VITRO  
Since increased phosphorylated levels of the extracellular-signal-regulated kinases (ERK1/2) 
promotes cell survival in CGNs [122], I measured levels of phosphorylated ERK1/2 in our HEK 
cells. Decreased phosphorylation of ERK1/2 in HEK-FTgpi and HEK-sFT cells was detected 
(Figure 2.26), suggesting that activation of the ERK1/2 signaling pathway could be impaired. 
The reduced activation of this pathway may contribute to toxicity. Again, in HEK-sFTΔHC cells, 
where the FTgpi lacks the HC domain, ERK1/2 was not down-regulated (Figures 2.26). Taken 
together, these data suggest that HC is required for triggering the cascade of events leading 
to neurotoxicity.  
 
 
Figure 2.26. FTgpi decreases ERK1/2 phosphorylation in vitro. Cell lysates were analyzed by Western 
blot using ERK1/2 and p-ERK1/2 antibodies. p-ERK1/2 /ERK1/2 ratio was calculated after values were 
normalized to actin. Each bar indicates the mean ±SEM of 3 biological replicates. *P<0.05 by unpaired 
two-tails t-test (each bar is compared to HEK-pcDNA5).  
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MICE EXPRESSING SFTΔHC DO NOT DEVELOP NEURODEGENERATION  
In order to confirm the previous results in vivo, I used the “half-genomic” pPrPHG vector to 
generate mice expressing the soluble secreted FT domain of PrPC (PrPΔ112-254 or sFTΔHC). The 
transgenic line sFTΔHC138 was selected and crossed with Prnpo/o mice to obtain offspring on a 
Prnpo/o background. sFTΔHC protein level was assessed by enzyme-linked immunosorbent 
assay ELISA to be 4.5% of total PrPC in BL6 brains (Figure 2.27A). sFTΔHC was detected on 
Western blot upon immunoprecipitation with POM2 and it appeared as a band at 12 kDa 
(Figure 2.27B).  
 
 
Figure 2.27. sFTΔHC138 mice do not develop neurodegeneration. (A) BL6, sFTΔHC138 and Prnp
o/o brain 
homogenates were analyzed by ELISA. Serially-diluted recombinant PrP23-231 (recPrP, red bars) was 
used to establish the standard curve. Upon data normalization, sFTΔHC138 mice (blue bar) were found to 
express a protein level of 4.5% compared to a BL6 mouse (green bar). (B) IP with POM2 was performed 
overnight on 10 mg of total protein (brain homogenate). The blot (stained with biotinylated-POM2) 
showed a band of ~ 12 kDa, corresponding to the sFTΔHC protein expressed by a transgene positive 
mouse (sFTΔHC138+/-). A transgene negative littermate (sFTΔHC138-/-) was used as negative control.  
 
sFTΔHC138 mice were observed for at least 700 days and were found to have a normal 
lifespan. In addition, they did not show motor alterations and did not develop 
neurodegeneration. H&E and GFAP staining of cerebellar sections from mice up to 90 weeks 
of age did not display any abnormalities (Figure 2.28).  
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Figure 2.28. sFTΔHC138 mice do not develop neurodegeneration. H&E and GFAP staining of paraffin-
embedded cerebellar sections from 90 weeks old Prnpo/o and sFTΔHC138 mice. sFTΔHC138+/- and 
sFTΔHC138-/- sections showed indistinguishable patterns. 
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DISCUSSION AND OUTLOOK 
We recently uncovered a critical role for the FT of PrPC as the effector domain of PrPC-
mediated neuronal death [99]. Ligands targeting the α1 and α3 helices of the PrPC globular 
domain induced rapid neurotoxicity in cerebellar organotypic cultured slices. Toxicity was 
prevented by deletions of the OR domain, suggesting that the FT has neurotoxic properties 
and is required to transmit the toxic signals originating from the globular domain [99]. In light 
of this data, we generated a mouse line expressing a membrane-anchored version of the FT 
(FTgpi) of PrPC and found the protein to be a potent neurotoxin. Mice expressing FTgpi 
developed severe ataxia and die within few weeks. Similar to other mice with interstitial PrP 
deletions (collectively referred to as “ΔPrP”) [56], FTgpi mice experienced massive loss of 
CGNs. However, the phenotype was not ameliorated (and was possibly exacerbated) by co-
expressing wild-type PrPC, indicating that the mechanism of toxicity differs from that of other 
ΔPrP mice. 
 
FTgpi induces chronic ER stress leading to neurodegeneration  
Unexpectedly, FTgpi retained the typical ER retention phenotype; however, only a small 
fraction of the protein was found to reach the plasma membrane. Degradation was 
predominantly mediatedby the proteasome, unlike the full-length protein which was mainly 
degraded by lysosomes. These observations, along with the unstructured nature of the 
protein and its exposed hydrophobic domain, led us to speculate that FTgpi may trigger ER 
stress. Interestingly, of the three branches of the UPR, FTgpi selectively activated the PERK 
pathway, which protects cells by transiently dampening cellular protein synthesis, thus 
reducing misfolded protein load and thereby restoring ER homeostasis [123]. However, when 
chronically activated, PERK signaling promotes cell death by inducing CHOP, which in turn 
promotes the transcription of Bcl-2-like protein 11 (BIM) [124,125], a proapoptotic protein, 
and by downregulating the antiapoptotic BCL-2 protein [125]. This cascade protects the 
organism from rogue cells in which the fidelity of their signaling components cannot be 
guaranteed [115].  
In many instances, the UPR tries to modulate the protein folding capacity of the ER by 
increasing the activity of the IRE1 and ATF6 pathways [71,115,116]. The activation of these 
pathways was not observed in FTgpi-expressing cultured cells, but mouse cerebelli exhibited 
a comprehensive ER stress response with significantly increased levels of spliced XPB1, BIP, 
CHOP and HSP40. This discrepancy may reflect the increased capacity of immortalized cells to 
deal with stress, activation of adaptive response pathways to deal with the stress, or the 
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secondary recruitment of multiple cell types in vivo. Apart from accumulating in the ER, the 
FTgpi also interacts with BiP, a key chaperone responsible for protein folding in the ER. The 
binding between BiP and FTgpi could sequester the availability of BiP to other essential 
proteins, which are its obligate substrates.  
The proposed signaling network elicited by FTgpi is represented in Figure 2.29. 
 
 
 
Figure 2.29. Scheme depicting the UPR pathways raised by FTgpi.  
 
Hydrophobic patterns are often targeted by the ER quality control machinery [126], and 
indeed removal of the hydrophobic core (HC) from FTgpi prevented hyperphosphorylation of 
eIF2α. In the context of FTgpi, the HC cannot be shielded by the folded globular domain of 
PrPC, which is missing. Thus, it could chronically engage a specific sub-module of the quality 
control, leading to ER stress and activation of PERK. 
Sustained PERK activation modulates AKT phosphorylation [121]. In particular, AKT activation 
is increased by short-term exposure, but is down-regulated by long-term exposure, to ER 
stress [127]. Accordingly, decreased phosphorylation of AKT was observed in both HPL and 
HEK cells. AKT has a highly conserved role in blocking apoptosis and promoting cell survival by 
regulating the activation of multiple downstream targets [128], thus chronic deactivation of 
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AKT may increase the susceptibility of CGNs to cellular stresses. The increased 
phosphorylation of AKT found in vivo but not in vitro. may result from the release of ATP by 
numerous apoptotic CGNs which in turn stimulates astrocytic AKT phosphorylation via P2Y 
receptors [129,130], contributing to the astrogliosis observed in older FTgpi mice. This 
suggests that, although AKT could be deactivated at the level of single CGN, it remains 
activated within the rest of the brain.  
Prolonged UPR activity is concomitant with chronic ER stress-associated cell death [131]. 
FTgpi-induced ER stress may cause the neuronal death observed in FTgpi mice. Importantly, 
ER stress was detectable in very young FTgpi mice, before any apparent histological or clinical 
signs of neurodegeneration. One interesting avenue to explore in future studies would be to 
see if pharmacological inhibition of PERK prevents neurodegeneration in FTgpi mice.    
 
Possible involvement of ER stress in human prion diseases  
Several mutations in the human prion protein gene (PRNP) have been associated with human 
prion diseases, such as Creutzfeldt-Jakob disease (CJD), Gerstmann-Sträussler-Scheinker 
syndrome (GSS) and fatal familial insomnia (FFI) [3]. The molecular mechanism by which 
these PRNP mutants lead to neurodegeneration is not well understood. Missense mutations 
can affect the structure of a protein, altering its subcellular localization, function, and 
structure, as demonstrated in a range of studies on the prion protein [132-137] as well as 
other proteins, such as the CFTR receptor [138] and the TPMT protein [139]. Evidence of ER 
stress has been found in humans affected with sporadic and vCJD [140] and in SH-SY5Y cells 
expressing a familial CJD-associated PrP mutant [141]. Therefore, we speculate that disease-
associated mutations in the PRNP gene introduce thermodynamic instability to the prion 
protein, which leads to a partial or total misfolding of PrP, exposing the HC, which could 
trigger the same pathway observed in FTgpi. In light of our new findings, the mechanism of 
toxicity of these mutant versions of PrPC clearly deserves further investigations.      
 
FTgpi as a model to investigate mechanisms of toxicity in prion infections 
ER dysfunctions have been observed in cases of prion infections. Nanomolar concentrations 
of purified PrPSc from mouse scrapie brain induce apoptosis in N2A neuroblastoma cells, and 
toxicity was associated with increased release of intracellular calcium from the ER, a strong 
upregulation of UPR-inducible chaperones, and a higher sensitivity to ER stress-induced cell 
death [142,143]. In another study, brain tissue samples from animals naturally infected with 
BSE showed upregulation of genes involved in ER stress responses, including ER chaperones, 
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heat shock proteins Grp94 and the chaperone Grp170 [144]. Further, abnormal upregulation 
of protein disulfide isomerase (PDI), Grp79 and Grp58 was detected in 263K infected hamster 
brain tissues [145].  
Recently, prion-infected mice showed sustained UPR induction, protracted eIF2α 
phosphorylation and PERK activation [67]. Repression of translation resulted in the loss of 
critical proteins that leads to synaptic dysfunctions and neuronal death [67]. Strikingly, this 
mechanism is similar to the signaling pathway evoked by FTgpi in transgenic mice. Although 
at this stage it is still unclear how the prion infection activates ER stress, one can hypothesize 
that the abrogation of the ubiquitin proteasome system within a prion-infected body could 
lead to accumulation of misfolded proteins in the ER, thereby inducing ER stress. Prion 
infections have been shown to impair post-Golgi trafficking of membrane proteins [146,147], 
therefore it is also reasonable to assume this could lead to the accumulation of such proteins 
in the ER resulting in ER stress. Alternatively, small amounts of PrPSc may enter the ER and 
activate ER stress, either by inducing the misfolding of the endogenous PrPC and exposure of 
its HC, and/or through direct binding to the UPR sensor IRE1 and PERK. In support of the 
latter, there is increasing evidence of direct binding of misfolded proteins to IRE1 and PERK 
and subsequent UPR activation [148,149]. A recent study showed that a specific compound 
targeting the PERK pathway of the UPR prevented neurodegeneration in prion-infected mice, 
both in animals treated at the preclinical stage and also later in disease [150]. 
 
ER stress and FTgpi: beyond prion diseases 
ER deregulation might have an important part to play in a range of other neurological 
disorders. Altered level of p-PERK, p-eIF2α and CHOP levels are seen in patients with 
Parkinson’s disease (PD) [68,151], Alzheimer’s diseases (AD) [69,152,153], Huntington’s 
disease (HD) [154,155], as well as in amyotrophic lateral sclerosis (ALS) [70,71]. Although the 
subcellular localization of protein misfolding can differ between these disorders, the 
interdependence of protein folding throughout the cells suggests that ER dysfunctions could 
be the final common pathway for many neurological diseases [156]. It is not well understood 
if ER stress is the cause or an effect of these diseases. UPR activation has been mostly 
detected in post mortem human brains and cell based models [157]. Animal models for AD, 
PD and HD often do not produce neuronal cell death [158], a major hallmark of these 
diseases, hence detection of signaling pathways evoked by these disorders could be 
problematic. 
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FTgpi pathogenesis suggests that ER stress is an upstream phenomenon in the chain of events 
leading to neurodegeneration, it is exacerbated by higher level of FTgpi, and it is a relatively 
slow and cumulative process, which leads in the long term to the death of CGNs. Being 
upstream, it could be a suitable target for therapeutic approaches. It is becoming increasingly 
clear that manipulation of common pathways such as protein translation and protein 
degradation, rather than disease-specific approaches, could lead to new, broader therapeutic 
strategies. Furthermore the resemblance between the mechanisms leading to 
neurodegeneration elicited by prions and FTgpi, suggest that FTgpi mice may represent a 
useful tool for further investigations of the mechanisms of toxicity underlying human prion 
diseases. Moreover, FTgpi mice are particularly suitable for assessment of potential new 
treatments, as ER stress occurs as an upstream event and is the main cause of toxicity. 
Therefore, we believe that FTgpi mice may represent a useful tool in the hunt for an effective 
treatment option.  
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MATERIALS AND METHODS 
Construction of transgenes 
To create the FTgpi construct, total mouse brain cDNA was amplified using the primer set SY6 
and SY7 which introduce BamHI and SalI cloning sites at the 3’ and 5’ ends of the ORF of PrP. 
PrP was cloned into the cloning vector pBSK (pBSK-PrP). This plasmid served as a template for 
the following cloning steps. An XbaI cloning site was introduced by PCR in the PrP ORF just 
before amino acid 225. The primer sets used were SY6/SY6a and SY7a/SY7. An amino-
terminal insert was amplified from pBSK-PrP using the primer set SY6/SY8 which introduces 
BamHI and XbaI cloning sites before the start codon and after amino acid 140, respectively. 
pBSK-PrP and the amino-terminal insert were digested with BamHI and XbaI, and the open 
vector and the insert were ligated, to generate a construct consisting of the first 140 amino 
acids of PrP directly linked amino acid 226 (PrPΔ141-225). Primers: SY6 fw (5’-CGC GGA TCC AAT 
TTA GGA GAG CCA AGC AGA-3’), SY6a rev (5’-CGC TCT AGA ACG TCG CCC GTC GTA ATA GGC-
3’), SY7a fw (5’-CGC TCT AGA GAC GGG AGA AGA TCC AGC AGC-3’), SY7 rev (5’-ACG CGT CGA 
CCA CGA GAA TGC GAA GGA ACA-3’), SY8 rev (5’-ACG CTC TAG ACC AGT CGT TGC CAA AAT G-
3’).  
To create the sFTΔHC construct, the “half-genomic” pPrPHG plasmid containing the wild-type 
PrP was used as template. Primer set BspE5’ and sFT3’ were used to generate a 2842bp 
amplicon containing the sFTΔHC sequence, and to introduce a BspEI and a StuI cloning sits at 
the 5’ and 3’ ends respectively. The “half-genomic” pPrPHG plasmid was then digested either 
with SalI and BspEI or SalI and StuI; an 8435bp and a 2379bp fragment were respectively 
isolated from gel, purified, and mixed with the previous amplicon in a three-way ligation 
reaction, in order to obtain the “half-genomic” pPrPHG plasmid expressing the sFTΔHC 
transgene. Primers: BstE5’ fw (5’-CAA GCA TTT AAG CCA GTC CGG AGC GGT GA -3’), sFT3’ rev 
(5’-CCT ATC TCA CAC ATG CTT GAG GTT GGT TTT TGG -3’). 
 
Generation of transgenic mice 
The phg plasmids containing the PrPΔ141-225 (FTgpi) ORF and PrPΔ112-254 (sFT) were propagated 
in Escherichia coli XL1 blue, the minigene were excised with NotI and SalI, processed as 
described [54], and injected into fertilized Prnp+/+ oocytes (B6D2F1/Crl) by standard 
procedures [159]. The transgene positive founders were crossed with Prnpo/o ZHI mice in 
order to obtain transgene-positive mice on a Prnpo/o background. FTgpi transgene was 
identified by PCR using the exon 2 forward primer pE2 and the non-coding region at 3’ of 
exon 3 reverse primer 3’NC . The fragment size of the transgene was 647bp. The sFTΔHC 
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transgene was identified by PCR using the forward primer pE2 and the reverse primer sFT3’. 
The fragment size of the transgene was 417 bp. In order to outbreed the Prnp+ allele, PCR 
analysis was carried out using primers P10 (forward primer, Prnp exon 3), 3'NC (reverse 
primer), and P3 (reverse primer, neoR gene); P10 and 3'NC gave a 542 bp signal for the Prnp+ 
allele and P3 and 3'NC gave a 362 bp product for the Prnp0 allele. In the PCR, the transgene 
was also detected as a 269 bp product. Primers: pE2 (5’-CAA CCG AGC TGA AGC ATT CTG CCT-
3’), 3’NC (5'-CCC TCC CCC AGC CTA GAC CAC GA-3’), P10 (5'-GTA CCC ATA ATC AGT GGA ACA 
AGC CCA GC-3’), P3 (5'-ATT CGC AGC GCA TCG CCT TCT ATC GCC-3’), sFT3’ rev (5’-CCT ATC 
TCA CAC ATG CTT GAG GTT GGT TTT TGG -3’).  
 
Morphological analysis 
Brains were removed and fixed in 4% formaldehyde in PBS, pH 7.5, paraffin embedded, and 
cut into 2-4 μM sections. Sections were stained with hematoxylin and eosin (H&E) and 
commercial antibodies to GFAP (glial fibrillary acidic protein; activated astrocytes). The same 
protocol was applied to livers, spleens, kidneys, hearts, stomachs, pancreas and intestines.  
 
TUNEL staining 
5 μM frozen sections were fixed with 1% paraformaldehyde in PBS, pH 7.4, for 10 min at 
room temperature (RT), rinsed twice in PBS, permeabilized with a solution of Ethanol:Acetic 
acid (2:1) for 5 min at -20°C, rinsed twice with PBS, and then stained using ApopTag® Plus In 
Situ Apopotosis Fluorescein Detection kit, according to the manufacturer’s directions 
(Millipore). Cell nuclei were counterstained with DAPI. Sections were mounted with 
Fluorescent Mounting Medium (Dako) and imaged on a CLSM Leica SP5 ZMB. Co-staining 
TUNEL and Iba1 on frozen sections: 5 μM slices were cut and put on glass slides, fixed 10 min 
in 1% paraformaldehyde in PBS, washed 2X with PBS, 2 min in 50% acetone, 2 min in 100% 
acetone, 2 min in 50% acetone, washed 2X with PBS and 1X with PBS-T. Slides were treated 
10 min with Protein block serum free (Dako), incubated 2 h at RT with Iba1 diluted in 0.3% 
Triton in PBS, washed 2X with PBS, 1X with PBS-T, incubated with anti-rabbit Alexa467 
secondary antibodies diluted in 0.3% Triton in PBS 1 h at RT with 1 ug/ml DAPI. Slides were 
washed 2X with PBS, 1X with PBS-T, and stained using ApopTag® Plus In Situ Apopotosis 
Fluorescein Detection kit, according to the manufacturer’s directions (Millipore). Sections 
were mounted with Fluorescent Mounting Medium (Dako) and imaged on a Olympus 
Fluoview FV10i. 
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Immunofluorescence staining 
Cells were grown on Cultureslides, 8-well (BD Biosciences), washed 1X PBS and fixed with 4% 
formalin in PBS, pH 7.4, for 15 min at RT. After washing 2X with ice-cold PBS, cells were 
permeabilized with 0.3% Triton X-100 in PBS for 5 min at RT, rinsed 1x with PBS, and 
incubated for 40 min in blocking solution (1% FBS in PBS) for 40 min at RT. Cells were rinsed 
1x with PBS and incubated with primary antibody (POM11, giantin, LAMP2) diluted in 
washing buffer (1%BSA, 0.25% Triton X-100 in PBS) overnight at 4°C. After washing 2X with 
PBS, cells were incubated with Alexa Fluor®-conjugated 555- anti-mouse or 647-secondary 
anti-rabbit or anti-rat antibodies (Invitrogen, Molecular Probes) diluted 1:5000 in washing 
buffer for 2 h at RT, and incubated with 1 ug/ml DAPI (4’,6-diamidino-2-phenylindole, 
Invitrogen). Permeabilization with 100% methanol at -20°C for 10 min was performed when 
calnexin was used as a primary antibody. Surface staining with CmDil: CM-Dil was diluted in 
cell culture media (OPTI-MEM, 10% FBS, Glutamax) at a concentration of 0.5 ug/ml, 
immediately before labelling. Cells were incubated at 37°C for 5 min, then at 4°C for 15 min, 
washed 1X with PBS and fixed in 4% formalin. Primary and secondary antibodies stainings 
were performed as previously described. Cells were mounted with Fluorescent Mounting 
Medium (Dako) and imaged on a CLSM Leica SP5 ZMB. Confocal imagines were processed 
with Imaris; colocalization was quantified using the function ImarisColoc after setting the 
thresholds.  
 
Generation of stably transfected Flp-InTM-293 cells 
Flp-InTM-293 cells were maintained in Dulbecco's Modified Eagle Medium (Life Technologies, 
31966-021) supplemented with 10% fetal bovine serum and penicillin/streptomycin. 
PrP, FTgpi, sFT and sFTΔHC constructs were cloned into the pcDNA™5/FRT vector. Flp-InTM-293 
cells were transfected with the respective pcDNA™5/FRT and pOG44 vectors using 
Lipofectamine 2000 (Invitrogen) according to the manufacturer’s directions. Clones were 
selected for 15 days in 250µg/ml Hygromycin and subsequently maintained in 100µg/ml 
Hygromycin.   
 
Western blot analysis 
Cerebellums were homogenized using TissueLyser LT for 5 min in 10 vol of lysis buffer (0.5% 
Nonidet P-40, 0.5% 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS), 
protease inhibitors (complete Mini, Roche), phosphates inhibitors (PhosphoSTOP, Roche) in 
PBS, and centrifuged at 1000g for 5 min at 4°C to remove debris prior to analysis by SDS-PAGE 
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(Novex® NuPAGE® 10% Bis-Tris Gels). After electrophoresis, samples were transferred to 
nitrocellulose membranes (PROTRAN®, Whatman®). Membranes were blocked with 5% milk 1 
h at RT and incubated overnight in Tris-buffered saline-Tween (TBS-T) at 4°C with primary 
antibodies, followed by incubation with a secondary Peroxidase-Goat Anti-Mouse IgG (H+L) 
(#62-6520) or Peroxidase-Goat Anti-Rabbit IgG (H+L) (#111.035.045), used at 1:10000 1 h at 
RT. Membranes were developed with Luminata Crescendo (Millipore) and images were 
acquired using Stella imaging system (Raytest). Cells were homogenized on ice using a 30G 
syringe in lysis buffer, centrifuged at 1000g for 5 min at 4°C to remove debris prior to analysis 
by SDS-PAGE (E-PAGE™ 48 wells 8%). After electrophoresis, samples were transferred using 
the iBlot system (Invitrogen). For deglycosylation, denatured total protein was incubated at 
37°C for 4 h with 500 U PNGase F (New England Biolabs) according to the manufacturer’s 
instructions.  
 
Immunoprecipitation 
Protein extraction from the mouse cerebellum was performed using mechanical lysis in IP 
buffer (HBS buffer (pH 6.8) with 2% CHAPS and cocktail of protease inhibitors (Roche)). This 
was followed by centrifugation at 8000 rpm for 10 min. The amount of protein in the lysate 
was estimated using BCA assay and 500 µg of the protein was used for the 
immunoprecipitation assays. For the cell lines, lysis was performed for 20 min at 4°C in IP 
buffer followed by centrifugation for 10 min at 10000 g. In both cases supernatants were 
precleared and incubated for 16 h at 4°C with antibodies and dynabeads. For 
immunoprecipitation of BiP 2 U/ml of Apyrase was added to the lysate to deplete ATP. After 
immunoprecipitation, the beads were washed for three times with the IP buffer and 
resuspended in the sample buffer (2x) after the final wash. The samples were heated at 95°C 
for 5 min and migrated on 12% Tris-Bis gels with the MOPS buffer.  
 
Pulse chase Assays 
To monitor the half-life of FTgpi and PrPC, HPL cells were transfected with mammalian 
expression plasmids of the two proteins. 24 h post transfection, the cells were either treated 
with DMSO, MG132 (10µM) or bafilomycin (250 nM) for 2 h followed by incubation in 
starvation medium (DMEM without methionine and cysteine) for 40 min along with the drugs 
to deplete the endogenous stores of methionine and cysteine. The cells were then labeled 
with 50µCi/ml 35S-methionine/cysteine for 20 min followed by a chase in normal medium at 
different time points. After the chase, the cells were harvested in isotonic HEPES buffer (pH-
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6.8) containing 2%CHAPS and protease inhibitor cocktail. Post nuclear supernatants were 
obtained by centrifuging the sample at 10000g for 10 min. FTgpi and PrPC were 
immunoisolated from the post nuclear supernatant by overnight incubation with POM2 
antibody followed by incubation with Dynabeads for 2h at 4°C. The immunoprecipitates were 
migrated on a 12% Tris-BIS gels followed by fixation and drying of the gels. The dried gels 
were exposed to phosphoscreen and the radiolabelled products were revealed using a film. 
 
Sandwich ELISA 
96-well plates were coated with 400 ng/ml of purified antibody POM2 overnight at 4°C. 
Plates were washed 4X with PBS containing 0.1% (vol/vol) Tween 20 (PBST), and blocked with 
5% TopBlock (Invitrogen) for 2hrs at RT. Plates were incubated with serially-diluted recPrP23-
231 for the standard curve, sFT138 (800 ug/ml), BL6 (100 ug/ml) and Prnpo/o (800 ug/ml) 
brain homogenates in PBST containing 1% TopBlock. After 2 h at RT, plates were washed 
extensively and then probed with biotinylated POM11 at a concentration of 100 ng/ml in 
PBST containing 1% TopBlock, for 1hr at RT. Subsequently, after washing, plates were 
incubated with horseradish peroxidase conjugated avidin (1:1000 dilution, Pharmigen) for 1h 
at RT. Plates were developed with TMB Stabilized Chromagen (SB01, Invitrogen), and optical 
density was measured at 450nm.  
 
FACS analysis 
Cells were harvested with EDTA 10 mM, washed 2X in PBS, resuspended in ice-cold FACS 
buffer (2%FBS, 2mM EDTA in PBS) and incubated with 1:500 POM11 antibody for 30 min on 
ice. Cells were then washed 2X with ice-cold FACS buffer and incubated for 30 min on ice with 
Alexa Fluor®-conjugated 647 anti-mouse, protected from light. Cells were washed 3X with 
ice-cold FACS buffer and transferred into micro-FACS tubes. Data was acquired using 
FACSCalibur™ (BD Biosciences).  
 
Antibodies 
Mouse monoclonal anti-PrP antibodies POM1, POM2, POM11 [1] were diluted 1:5,000 for 
Western blot; anti-PERK (#3192), anti-p-PERK (#3179), anti-eIF2α (#9722), anti-p-eIF2α 
(#9721), anti-CHOP (#5554), anti-AKT (#4685), anti-p-AKT (#4060), anti-Erk1/2 (#9107), anti-
p-Erk1/2 (#4370) (Cell Signaling) were diluted 1:1000 for Western Blot; actin antibody 
(Millipore AG, MAB1501R) was used at 1:10000 for Western blot. Immunofluorescence: anti-
calnexin (Abcam, ab22595) was used at 4 ug/ml, anti-giantin (Abcam, ab24586) was used at 
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1/1000, anti-lamp2 (Abcam, ab25339) was used at 1/100, anti-Iba1 (Abcam, ab5076) was 
used at 1/100, and POM11 was used at 1/1000. Co-staining TUNEL and Iba1: anti-Iba1 (Wako, 
019-19741) was used at 1:500.  
 
mRNA analysis 
Cerebellar RNA was isolated using RNeasy Plus Universal Mini Kit (QIagen), according to the 
manufacturer’s manual. After reverse transcription (QuantiTect Rev. Transcription Kit, 
QIagen), cDNA was used for RT-PCR to quantify FTgpi and PrP mRNA levels using the 
following primers: pE2 fw (5’-CAA CCG AGC TGA AGC ATT CTG CCT-3’), sFT ORF rev (5’-AGG 
TGC CAC CCT GAG GTG GGT AA-3’). GAPDH was used to standardize expression levels using 
primers GAPDH fw (5’-CCA CCC CAG CAA GGA GAC T-3’) and GAPDH rev (5’-GAA ATT GTG 
AGG GAG ATG CT-3’). RT-PCR was performed using SYBR-green (Roche) and determination of 
ΔΔCT-values was done on a ViiA™ 7 real-time system (Applied Biosystems). Cell mRNA was 
isolated using RNeasy Mini Kit (QIagen), according to the manufacturer’s manual. After 
reverse transcription (QuantiTect Rev. Transcription Kit, QIagen), cDNA was used for RT-PCR 
to quantify the ER stress related genes; CHOP: fw (5’-CTT CAC TAC TCT TGA CCC TGC-3’), rev 
(5’-CTA GTT CTT CCT TGC TCT TCC TC-3’). Spliced-Xbp1 primers: fw (5’-TGC TGA GTC CGC AGC 
AGG TG-3’), rev (5’-CAT GAC AGG GTC CAA CTT GTC-3’). BIP primers: fw (5’-CGA GGA GGA 
GGA CAA GAA GG-3’), rev (5’-CAC CTT GAA TGG CAA GAA CT-3’). HERP 1 primers: fw (5’-CAT 
CTC TAG GCC TGA GGC TG-3’), rev (5’-GTT CCT GAT GCA GCA GTG GCA-3’). ERP72 primers: fw 
(5’-TGG ACA CCT CCA CCT GAA GTC-3’), rev (5’-CTC ATA CTC AGG GGC AAG TTT C-3’). HSP40 
primers: fw (5’-GAT CTG CCA CTG CTT CTC TAA G-3’), rev (5’-CCT GAG CAG CTT CAT AAT CC-
3’). EDEM1 primers: fw (5’-GTT CTG ATA GGG GAT GTG GAA G-3’), rev (5’-GAG GAG ATA TGT 
GGA CTC CAC-3’). GAPDH was used to standardize expression levels. RT-PCR was performed 
using SYBR-green (Roche) and determination of ΔΔCT-values was done on a ViiA™ 7 real-time 
system (Applied Biosystems). 
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CHAPTER 3 
OVEREXPRESSION OF SHADOO IN PERIPHERAL NERVES DOES 
NOT RESCUE THE POLYNEUROPATHY IN PRNPO/O MICE 
INTRODUCTION 
SHADOO, A PROTEIN WITH SIMILARITY TO THE PRION PROTEIN FT  
Shadoo (Sho) is the third member of the prion gene family, and was discovered in 2003 by in 
silico analysis. The protein was coined Shadoo, the Japanese word for ‘shadow’, and the gene 
was termed Sprn (‘shadow of the prion protein’), and appeared to be widely conserved in 
nature [98]. Sho was predicted to be extracellular and GPI-anchored, which was then 
confirmed experimentally [97]. Sequence comparison with PrPC shows: a highly conserved N-
terminal signal sequence and a hydrophobic region of 20 residues with strong homology. 
Furthermore, although Sho does not have an octarepeat domain, it has an Arginine-rich basic 
region containing up to six tetrarepeats. Conversely, the C-terminal of Sho contains a 
glycosylation site but no structure, hence it has little homology with PrPC GD [98] (Figure 3.1). 
The circular dichroism spectrum of recombinant murine Sho is consistent with a random coil 
configuration [97]. Overall, Sho strongly resembles PrPC FT.        
Unlike Doppel, Sho expression is restricted to the CNS, which may have implications for prion-
associated CNS phenomena. Initial findings led to the hypothesis of a possible functional link 
between mammalian PrP and Sho proteins.     
 
 
 
Figure 3.1 Structural comparison between PrP and Sho. Sho resembles PrP FT. In particular, the 
hydrophobic tract (in dark grey) shares high homology.     
 
Prnpo/o mice show only a mild phenotype despite PrPC being implicated in multiple cellular 
processes. Therefore, it has been hypothesized that an alternative protein (π) exists, which is 
able to compensate for the absence of PrPC [91] in vivo. Following its discovery, investigators 
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appointed Sho as the π protein, primarily because of the high homology of the HC domain 
(Figure 3.1). The HC domain, as previously mentioned, is crucial for PrPC neurotrophic 
properties and myelin maintenance.   
 
SHADOO HAS PRPC-LIKE PROTECTIVE PROPERTIES 
ΔPrP mutants and Doppel are able to induce cell death when transfected into wild type 
cerebellar granule neurons (CGNs) [97,103]. As anticipated, cotransfection of wt PrPC reduced 
the toxic activity of both ΔPrP and Doppel in this model. Interestingly, cotransfection of wt 
Sho also significantly ameliorated the toxic phenotype of ΔPrP and Doppel [97]. Given the 
similarities between the HC domains of Sho and PrP, and HC intrinsic properties, this domain 
was a strong candidate for the ‘active site’ of Sho. Therefore, a mutant version of Sho lacking 
the HC domain was generated (ShoΔ62-77). When cotransfected in CGNs along with Doppel and 
ΔPrP, ShoΔ62-77 could not exert its neurotrophic effect [97]. Moreover, knockdown of Sho in 
Prnpo/o embryos induced lethality [160]. Taken together, these results pointed at Sho as the 
potential π protein.   
 
SHADOO IN PRION INFECTIONS 
Sho protein level is strikingly reduced in prion-infected animals, whereas no differences were 
observed in mice models of Alzheimer’s disease, suggesting Sho depletion may be specific for 
prion diseases [97]. 
Follow-up experiments showed that Sho protein levels were decreased in the brains of mice, 
hamsters, voles, and sheep infected with different natural and experimental prion strains. 
Furthermore, Sho levels were inversely proportional to levels of PrPSc [161].  
Its apparent involvement in prion diseases led to investigators to believe that Sho may offer 
new insights into the homeostatic mechanisms involved in detection and clearance of 
misfolded proteins that drive prion disease pathogenesis.   
Therefore, mice overexpressing Sho, driven by the Prnp promoter, were generated 
(TgSprnp24551 mice) [162]. In these mice, levels of Sho are 2.5-fold higher than the 
endogenous protein, whereas PrPC level is not altered. When TgSprnp24551 mice were 
challenged with prions, the incubation period and onset of clinical symptoms were not 
different between the various cohorts, suggesting that Sho does not modulate the chemical 
events that shape the neurological disease phase of prion infection [162]. Nevertheless, 
scientists concluded that the potent drop in Sho protein occurring during the preclinical 
phase of the disease could be used as a marker for early detection of prion infections. 
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SHADOO IS NOT THE Π PROTEIN 
Westaway and coworkers generated Sho knockout mice (Sprno/o mice) [163]. Sprno/o mice are 
viable and have a normal life span. Prion-infected Sprno/o mice have incubation times and 
clinical symptoms that are not notably different from prion-infected wild type mice [163]. 
Importantly, double-knockout mice deficient in both Sho and PrPC (Sprno/o Prnpo/o) are also 
fertile and viable up to a mean of 690 days of age [163]. These data reduce the impetus for 
equating Sho with the notional π protein, and contradict the previous results that showed 
lethality in double-knockout embryos.   
 
OUTLINE OF THIS WORK 
Mice lacking the HC of PrPC or Prnpo/o mice develop CDP in the peripheral nerve but not in the 
CNS [2] [81], suggesting that HC is essential for peripheral myelin maintenance. Sho carries a 
domain with high homology to the HC of PrPC and it has been shown to have PrPC-like 
neuroprotective features.  
I posit that, because Sho is expressed in the CNS and is functionally homologous to the 
neuroprotective function of the HC of PrPC, it therefore rescues the CDP phenotype (in the 
CNS) induced by HC-deficient mice. The abrogation of the CDP does not occur in peripheral 
nerves, possibly due to the lack of Sho expression. Therefore, I wished to test the hypothesis 
that expression of Sho in the peripheral nerve would prevent CDP in Prnpo/o mice. 
Mice expressing ~2.5-fold transgenic Sho, driven by the Prnp promoter, were kindly provided 
by Dr. David Westaway (University of Alberta, Centre for Research in Neurodegenerative Diseases) 
and crossed with Prnpo/o mice. In these mice, I found that Sho does not revert the CDP 
phenotype present in the peripheral nerves, thus refuting our initial hypothesis, and 
contributing to the evidence indicating that Sho is not the potential partner/surrogate of 
PrPC. 
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RESULTS 
SHADOO IS NOT EXPRESSED IN PERIPHERAL NERVES 
Sho is predominantly expressed in the CNS, although limited expression of Sho has been 
detected by RT-PCR in non-brain tissues such as lung and stomach [98]. Sho has not been 
detected in testis, liver, gut spleen, heart, kidney and skeletal muscle [98]. The expression of 
Sho in peripheral nerves has not previously been investigated.   
In order to assess the expression of Sho in peripheral nerves, I collected whole brains (as 
positive controls) and dorsal root ganglions (DRGs) from wild type mice; extracted the mRNA, 
translated into cDNA, and multiplied by a 40 cycles PCR reaction. I used two different pairs of 
primers, one pair annealing to the 3’ untranslated region (Sho_3’ primer) and one pair 
annealing to the ORF (Sho_ORF primer) of the Sprn gene. Actin was used an additional 
positive control for the PCR reaction and quality of cDNA. As anticipated, I detected Sho in 
brain cDNA, whereas I could not detected a signal in DRG cDNA, indicating that Sho is not 
expressed in peripheral nerves (Figure 3.2).   
 
 
 
Figure 3.2. Sho is not expressed in peripheral nerves. mRNA was obtained from mouse tissue whole 
brains and dorsal root ganglions (DRGs) of wild type mice. Sho signal was selectively detected in the 
brain tissue but not in DRGs, indicating that Sho is absent in peripheral nerves.   
 
GENERATION OF TRANSGENIC MICE OVEREXPRESSING SHADOO ON A PRNP0/0 BACKGROUND 
PrPC is physiologically expressed in the peripheral nervous system, thus the Prnp promoter 
allows the expression of the gene in peripheral nerves [76]. Mice overexpressing transgenic 
Sho ≈ 2.5 fold under the Prnp promoter (TgSprn24551 or Sprn) [162], originally on a FVB 
genetic background (Prnp+/+), were crossed with Prnpo/o mice in order to obtain a mouse line 
over-expressing Sho, driven by the Prnp promoter, on a Prnpo/o background (Figure 3.3).  
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The CDP observed in Prnpo/o mice has 100% penetrance at 50 weeks [81]. Therefore, once the 
new line was established, mice were aged up to 50 weeks and, only then, were subsequently 
examined.  
 
 
 
Figure 3.3. Breeding strategy. Sprn mice were crossed twice with Prnpo/o mice in order to obtain the 
mouse line Sprn+/- Prnpo/o 
 
SHADOO DOES NOT RESCUE THE POLYNEUROPATHY OBSERVED IN PRNP0/0 MICE 
Sciatic nerves were collected from 50 week-old Sprn+/- Prnpo/o, Sprn-/- Prnpo/o and Sprn-/- 
Prnp+/o littermates. Sprn-/- Prnp+/o mice were used as a ‘healthy nerve’ positive control, as 
these mice still retain a Prnp allele; Sprn-/- Prnpo/o mice were used as a ‘degenerated nerve’ 
positive control [81].  
Representative toluidine blue-stained ‘semi-thin’ cross sections of sciatic nerves are shown in 
Figure 3.4 
As anticipated, no signs of neuropathy were detected in Sprn-/- Prnp+/o mice. Conversely, all 
Sprn+/- Prnpo/o and Sprn-/- Prnpo/o mice that were included in these assessments showed CDP, 
which was 100% penetrant and conspicuous in all peripheral nerves (Figure 3.4). Structural 
CHAPTER 3 RESULTS 
 
69 
abnormalities, such as aberrant or redundant myelin loops and supernumerary myelin 
sheaths were detected in both Sprn+/- Prnpo/o and Sprn-/- Prnpo/o mice. Morphological 
alterations in Sprn+/- Prnpo/o mice were less pronounced, yet qualitatively similar to those of 
Sprn-/- Prnpo/o mice (Figure 3.4).  
 
 
 
Figure 3.4. Sprn+/- Prnpo/o mice are affected by CDP. Toluidine blue-stained ‘semi-thin’ cross sections of 
sciatic nerves of Sprn-/- Prnp+/o, Sprn+/- Prnpo/o and Sprn-/- Prnpo/o mice, all approximately 50 weeks of 
age. Sho does not rescue the CDP observed in Sprn-/- Prnpo/omice. 
 
I used software developed in house [81] to analyze the axon size-density distribution in these 
nerves. Large fibers were predominantly found to be affected by the lack of PrPC, as 
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previously reported [81], and Sho was found not to be able to revert the phenotype, although 
a very mild effect was observed for axons of 45-50 µm2 (Figure 3.5).  
 
 
 
Figure 3.5. Sho does not revert the phenotype induced by the lack of PrPC. Morphometrical analysis of 
sciatic nerves. Axonal density within nerves (number of axons per mm2) was quantified 
morphometrically and plotted against the cross-sectional areas (µm2) of axons (axonal density-size 
distribution). Error bars, s.e.m.  
 
In conclusion, our studies indicate that Sho does not significantly influence the onset and 
development of CDP associated with the lack of PrPC in adult mice. 
 
BEHAVIORAL EXPERIMENTS   
I performed a series of behavioral experiments (hot plate test, grip test, rotarod) to identify 
any subtle differences between Sprn+/- Prnpo/o and Sprn-/- Prnpo/o mice.  
In the hot plate assay, the mouse is placed on the surface of a hot plate, which is maintained 
at 52.5 °C [164]. The latency of the mouse to raise and lick hind paws, to flutter or to jump up 
is recorded. The latency of these reflexes is dependent, among other variables, upon the time 
for afferent conduction of the impulse coming from the peripheral system to the spinal cord 
dorsal horn neurons [165]. 
Our group previously reported that the time lag to licking was significantly longer in Prnpo/o 
mice compared to wild type mice [81]. Therefore, I wished to test whether Sho was able to 
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decrease the response of Prnpo/o mice to heat. Responses were found to be not significantly 
different between Sprn+/- Prnpo/o and Sprn-/- Prnpo/o mice, both at 13-18 weeks and 50 weeks 
of age (Figure 3.6), reinforcing the histological observation that Sho does not ameliorate the 
CDP.  
 
 
 
Figure 3.6. Hot plate test. Mice were individually placed onto a metal plate that was maintained at a 
constant temperature of 55°C (± 0.4°C). The time to a response to the heat, such as shaking of the hind 
paws, licking of the hind paws and jumping, was recorded. Responses to heat were not significantly 
different between Sho +/- and Sho -/- mice. All mice are on a Prnpo/o background 
     
 
The grip strength test is used to measure the neuromuscular function, as maximal muscle 
strength of forelimbs and combined forelimbs and hind limbs. These are assessed by the 
grasping applied by the mouse on a grid that is connected to a sensor [165]. I previously 
observed that grip strength was significantly weakened in 50-week-old Prnpo/o mice 
compared to the controls [81]. Here, I assessed if there was any difference in strength 
between Sprn+/- Prnpo/o and Sprn-/- Prnpo/o mice, and found that there was no significant 
difference in performance between the two groups (Figure 3.7). 
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Figure 3.7. Grip strength test. Each mouse was pulled by the tail and thus exerted a force on the wire, 
which was attached to a mechanical spring force gauge calibrated in Newton. No statistically 
significant differences in grip strength were observed between Sho +/- and Sho -/- mice. All mice are on 
a Prnpo/o background. 
 
Motor coordination, balance and ataxia can be tested with the rotarod test. The rotarod 
measures the ability of the mouse to maintain balance on a rotating rod [166]. This task 
requires an intact cerebellar function and motor coordination [167]. 
On accelerating rotarods, the time to fall was similar for 13-18 weeks and 50-week-old Sprn+/- 
Prnpo/o mice compared with their negative (Sprn-/- Prnpo/o) littermates (Figure 3.8).    
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Figure 3.8. Rotarod test. Mice were placed on accelerating rotating drums. The time to fall was 
evaluated when the animals dropped from the drums. Sho +/- mice showed no difference in 
performance on the rotarod test when compared to Sho-/- mice at 13-18 weeks (left panel) and 50 
weeks of age (right panel).  All mice are on a Prnpo/o background.  
 
In agreement with the histological results, all behavioral experiments suggest that Sho does 
not ameliorate the CDP at the level of peripheral nerves, as no differences were observed 
between Sprn+/- Prnpo/o and Sprn-/- Prnpo/o mice. 
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DISCUSSION AND OUTLOOK 
In this study, I demonstrated that specific overexpression of Sho in peripheral nerves of 
Prnpo/o mice could not alleviate the CDP which invariably affect these animals. Histological 
examinations and behavioral experiments showed that Sho does not influence the 
development of the polyneuropathy. Sections of sciatic nerves from Sprn+/- Prnpo/o still 
displayed the classic hallmarks of the CDP, such as aberrant or redundant myelin loops, 
supernumerary myelin sheaths and axon morphology irregularities, which has been 
previously described [81]. Moreover, no differences were observed from a battery of 
behavioral experiments. Taken together, these results clearly reject our initial hypothesis that 
Sho could act as the substitute protein for PrPC in the CNS, where Sho is expressed and where 
no CDP in observed in Prnpo/o mice.  
   
At the initiation of this project, there was a paucity of knowledge concerning Sho. I knew the 
similarities between Sho and FT of PrPC, and evidence that indicated the PrPC-like 
neuroprotective activity of Sho in a range of assays in vitro [97]. Furthermore, double 
knockout of Prnp and Sprn in mouse embryos induced embryonic lethality [160]. These early-
stage results and the firm desire of the scientific community to identify the physiological 
function of PrPC, led to the speculation that Sho, defined as the shadow of PrPC, is the π 
protein and potentially the substitute/partner to PrPC in signaling and in the involvement in 
prion diseases.  
Follow-up studies have, however, reduced the hype surrounding Sho. The most important 
report came from Westaway et al, who generated a double knockout mouse (Sprn-/- Prnpo/o) 
which was viable and fertile up to 690 days, contrary to expectations [163]. Furthermore, 
absence of Sho did not significantly impact the temporal and clinical manifestation of prion 
infections. Overall, these results reduced the impetus for associating Sho with the π protein.  
 
Although Sho has some PrPC-like protective properties [97], and could be useful as a marker 
of prion infections [162] and to dissect the behavior of PrPSc in the cell [161], Sho is not 
involved in myelin maintenance, as initially hypothesized, therefore, the identity of the 
substitute protein still remains elusive and subject to investigation. Nonetheless, this work 
provides further knowledge on the role and function of Sho.   
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MATERIALS AND METHODS 
Mice 
We housed mice and performed animal experiments in accordance with the Swiss Animal 
Protection Law and in compliance with the regulations of the veterinary office (canton 
Zürich). We included the following mice in our study: Prnpo/o on a mixed C57BL/6;129Sv 
background [60]. We bred FVB/NCr-Tg(HaPrPcos-Sprn)24551/Mri mice (TgSprn24551 or Sprn) 
[162] with Prnpo/o mice to obtain Sprn+/- Prnpo/o and Sprn-/- Prnpo/o. 
 
PCR analysis  
Whole brains and DRGs were extracted from wild type mice. mRNA was isolated using 
RNeasy Plus Universal Mini Kit (QIagen), according to the manufacturer’s instructions. 
Following reverse transcription (QuantiTect Rev. Transcription Kit, QIagen), cDNA was 
amplified by PCR to detect Sho using the following primers: Sho_3’ fw (5’-TGT TTA GCA TCT 
GGC ACA GC-3’), Sho_3’ rev (5’-GAT GGC TGA TAG CAG GGG TA-3’), Sho_ORF fw (5’-CTG GAG 
GAC GAT GAG AAT GG-3’), Sho_ORF rev (5’-GAA GCA GTT CTA GGG CAC CA-3’), actin fw (5’-
GAC AGG ATG CAG AAG GAG AT-3’), and actin rev (5’-TTG CTG ATC CAC ATC TGC TG-3’).  
PCR parameters: denaturation (94°C, 2 min), 40 cycles amplification (three steps: 94°C, 30 
sec_55°C, 30 sec_72°C, 50 sec), final elongation (72°C, 5 min).  
 
Ultrastructural investigations 
We embedded sciatic nerves in Epon using standard procedures and stained ‘semi-thin’ 
sections (500 nm) with toluidine blue. For morphometric analysis of axon size-density 
distribution, we captured images of ‘semi-thin’ sections from three mice per genotype and 
analyzed these using a semi-automatized software developed in house. We plotted axonal 
density against axonal size.   
 
Behavioral experiments  
In order to assess the functionality of the peripheral proprioceptive system, muscle strength, 
locomotion and motor coordination in mice, hot plate test, grip strength test and RotaRod 
were used respectively. Tests were performed on consecutive days to allow the mice to 
recover between each testing session. 
Hot Plate Test: during the hot plate test, the animals were individually placed onto a metal 
plate (ITC Life Science, Series 8, PE 34, Woodland Hills, USA) that was maintained at a 
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constant temperature of 55°C (± 0.4°C). The time to a response to the heat, such as shaking 
of the hind paws, licking of the hind paws and jumping (all 4 paws in the air), was recorded. 
Each test was stopped after 60s.  
Grip Test: the test consists of a mechanical spring force gauge, calibrated in Newton with a 
maximal capacity of 3N (Medio-Line Spring scale, metric, 300g, Pesola AG, Baar, Switzerland), 
which is attached to a trapezoidal steel wire for mice to grasp. Each mouse was pulled by the 
tail and thus exerted a force on the wire. When the pulling force applied on the wire 
exceeded the grip strength, the mouse would let go of the wire and the force indicated on 
the gauge was determined. The grip strength was measured five times per mouse, and then 
the median value for each animal was captured for statistical analysis. 
Rotarod: the Rotarod consists of five rotating drums which accelerate continuously from 4 to 
40 rpm (Ugo Basile, model 47600, Comerio, Italy). The maximum speed was attained after 
245s. Five animals were tested simultaneously and the time and number of rotations was 
evaluated when the animals dropped from the drums (cut off time was 300s). The test was 
repeated five times per animal and the mean values per mouse were captured for statistical 
analysis. 
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